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Background: Depression is a common mental disorder and a major contributor to the overall 
global burden of disease. Healthcare systems struggle to provide effective and acceptable 
treatment to meet the needs of the growing number of patients suffering from depression. 
Although there are some known, effective medical treatments for depression, far from all of 
those affected receive such treatments, and there is a corresponding patient- and stakeholder 
demand for drug-free alternatives to treat depression. Group psychoeducation is a low 
threshold, drug-free intervention which has proven to be beneficial in the treatment of other 
mental disorders and which can be adapted to different populations. Use of group 
psychoeducation for major depressive disorder (MDD) will increase the availability of 
treatment, if proven to be effective, because it allows for treating several patients in the same 
session and meets calls for drug-free treatment.  
Objective: To systematically review the effectiveness of group psychoeducation for adults 
with MDD, as sole treatment or in conjunction with treatment as usual (TAU), compared to 
pharmacological treatment and/or other psychological treatment. Included effect measures are 
quality of life, depression severity, mortality (suicide), psychosocial functioning, relapse, and 
compliance.  
Methods: The review was planned and described in a PROSPERO (CRD42017077110) 
registered protocol. The search strategy was executed by a search librarian and it was peer 
reviewed by another librarian. The search included electronic searches in MEDLINE, 
Embase, the Cochrane Library, PsycINFO, PubMed, CINAHL, Epistemonikos and a hand 
search of 29 systematic reviews. The search yielded a total of 4219 records, which were 




the Cochrane risk of bias tool for RCTs. We conducted meta-analyses when studies were 
sufficiently similar in terms of design, population, intervention, and outcomes. Lastly, we 
evaluated the certainty of the body of evidence using the GRADE approach.   
Results: Nine randomized controlled studies (RCTs) with a total of 1249 patients met the 
inclusion criteria. The meta-analytic results showed that group psychoeducation in 
conjunction with TAU compared to TAU lead to a reduction in depression at 4-6 weeks, 
SMD= -0.32 (95% CI: -0.59 to -0.04), and 6 months, SMD= -0.21 (95% CI: -0.38 to -0.04). 
The effect of psychoeducation in conjunction with TAU was not significant at 12 months 
follow up, SMD= 0.22 (95% CI:-0.02 to 0.45). Family psychoeducation (groups including 
patient and caregiver) in conjunction with TAU showed a greater effect on depression than 
patient group psychoeducation. This was particularly prominent at 3 months follow-up, 
SMD= -1.21 (95% CI: -1.64 to -0.78). Family psychoeducation in conjunction with TAU also 
showed greater effect than TAU alone on psychosocial functioning at 3 months follow-up, 
SMD= 0.98 (95% CI: 0.56 to 1.40). The confidence in the certainty of the evidence varies 
from high to low. Results for psychosocial functioning was downgraded due to small sample 
size.   
Conclusions: While the current body of research on group psychoeducation shows promise 
for its effects on depression and psychosocial functioning, further evidence on the short- and 
long-term effects is needed. Family group psychoeducation seems to give better results than 
patient group psychoeducation. Robust studies to build a solid evidence on the effect of 
psychoeducation and knowledge on the effects for different patient groups in various 
socioeconomic- and cultural settings are necessary, prior to a generalised recommendation on 
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1 Introduction      
Although many patients with mental health disorders benefit from psychiatric care, a 
considerable proportion of such patients have limited access, do not want to take drugs, 
respond poorly or experience adverse effects (Vaaler & Fasmer, 2013). When patients have 
the capacity to provide informed consent and state that they do not want to be medicated, they 
should not be forced to, as long as there are alternative, drug-free treatments and care 
available (Brev fra Helse- og omsorgsdepartementet til de regionale helseforetakene, 2015). 
Responding to user organisations’ calls for the introduction of drug-free treatment alternatives 
in mental health care, in November 2015, the Norwegian Ministry of Health instructed all the 
regional health authorities to provide medication-free treatment options (Brev fra Helse- og 
omsorgsdepartementet til de regionale helseforetakene, 2015). However, according to 
Norwegian psychiatric user organizations (regjerningen.no, 2015), the supply of non-medical 
treatment is inadequate. Further, drug-free alternatives challenge the conventional view of 
what is ethical psychological treatment (Njaa, 2018), and some argue that drug-free programs 
are “an uninformed measure” that lack evidence (Røssberg, 2017).    
Psychoeducation (PE) is a drug-free, psychological treatment that has proven to be beneficial 
for patients suffering from psychosis and bipolar affective disorder, but there is currently a 
knowledge gap regarding psychoeducation for major depressive disorder (McFarlane, 2016).  
The purpose of this Master thesis in Public Health is to identify and summarize research on 
the effects of group PE compared with pharmacological and/or other psychological treatment 
for patients suffering from major depressive disorder. Given that psychoeducation typically is 
given in conjunction with usual psychological care, it is relevant to examine studies of both 




treatment. The aim of this review is to improve the knowledge base on the effects of PE as a 
drug-free adjunct treatment and PE as a drug-free sole alternative for patients with major 
depressive disorder. 
1.1 Background      
 
Depression is one of the most common mental disorders with more than 300 million people of 
all ages affected globally (WHO, 2018). According to the Norwegian Institute of Public 
Health, about 12-15% of the population at any time are affected by depression (fhi.no, 2015). 
Depression may become a serious health condition when it is long lasting, or when the 
intensity is moderate or severe. According to WHO, depression is the leading cause of disease 
burden globally, and it is on the rise (WHO, 2018). Major depressive disorder (MDD) and 
dysthymia accounted in 2010 for 2.5% of global Disability Adjusted Life Years (DALYS), a 
measure of reduced health year, and it is also associated with lower work productivity, suicide 
and ischemic heart disease (Ferrari, 2013). According to WHO, persons with MDD and 
schizophrenia have a 40-60% greater chance of dying prematurely compared to the general 
population. Depression can lead to suicide. Close to 800,000 people die of suicide every year 
due to all causes (WHO, 2018). Reduction in healthy life years and the associated health 
issues due to depression has not only an impact on the affected persons and their families but 
also on the economy worldwide (WHO, 2016). 
Disease specific pharmacological treatment for depression is antidepressant medication. 
According to the National Institute of Mental Health (The National Institute of Mental Health, 
2016), the most common antidepressant medications are: Selective Serotonin Reuptake 
Inhibitor (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), Bupropion, 





There are many non-medical interventions for depression disorder. Cochrane Common 
Mental Disorder lists 87 different psychological therapies (Cochrane CCDAN, n.d.).  
Despite the range of treatment options for depression, globally, fewer than half of those 
affected receive treatment for their depression, and in some countries less than 10% receive 
treatment (WHO, 2018). Reasons include lack of resources, lack of trained health care 
providers, inaccurate diagnostic assessment, and social stigma associated with mental 
disorders (WHO, 2018). 
To fulfill the Norwegian government’s goals of providing effective and safe medication-free 
treatment for people suffering from depression, the treatment options on offer to the patients 
need to be evidence based. If proven to be effective, group psychoeducation (GPE) is a low-
cost treatment that can be made widely available. It also has the potential to reduce the social 
stigma of psychiatric illnesses, because the format of the treatment is a course rather than a 
therapy, intending to reach people who otherwise may not seek formal treatment (Dowrick, 
2001).  
The Norwegian Institute of Public Health recently conducted a systematic review aiming to 
evaluate the effect of different psychosocial therapies without use of antipsychotics for 
patients with active psychosis. The literature search yielded no relevant studies where 
psychosocial treatment was given in conjunction with antipsychotic medication (Holte, 2017). 
Thus, we foresee a two-step approach in evaluation of the effectiveness of GPE. If GPE 
proves to be effective in conjunction with traditional psychotherapy and/or antidepressant 
medications, the logical next step would be to conduct research on the effectiveness of drug-





1.2 Patient perspective 
In 2011, patients and their dependants established the initiative «Fellesaksjonen for 
medisinfrie behandlingsforløp» in Norway. This stakeholder initiative’s sole purpose was to 
advocate for drug-free alternatives in treatment of psychiatric illnesses. Pressure from 
«Fellesaksjonen for medisinfrie behandlingsforløp» resulted in the 2015 instruction from the 
Norwegian ministry of health and care services to all regional health care authorities, 
demanding provision of drug-free alternatives in psychiatric care, in all regions (Brev fra 
Helse- og omsorgsdepartementet til de regionale helseforetakene, 2015).    
The patients and other stakeholders were, and are still, arguing that medication is often 
perceived as involuntary treatment (Njaa, 2018) with undesirable side effects. The degree of 
undesirable side effects can be substantial. In one study (Singh, Liliah & Montagene, 2016), 
53.3% of patients on antidepressants reported personality change, and 63.6% of patients 
reported dependency of their medication, but 88.6% did not feel addicted. Undesirable side 
effects were reported to be the main cause of non-adherence to treatment.  
Respect for the patient’s integrity should be of paramount importance to anyone supplying 
healthcare, therefore research into drug-free alternatives can easily be justified.  
1.3 Description of the condition   
A depressive episode can be categorized as mild, moderate, or severe depending on the 
number and severity of symptoms (WHO, 2018). The 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10) (WHO, 2016) 
defines different clinical diagnoses of depression. Major depression disorder (MDD) is an 




2018). During a severe depressive episode, it is unlikely that the person will manage to 
function well enough to maintain work and social activities (WHO, 2018).  
1.4 Description of the intervention   
Psychoeducation is defined as a didactic approach aiming to give the participants sound 
knowledge of the condition and learn how to accept it and cope with it successfully (Ekhtiari, 
2017). The intervention can be used for many different conditions. It can include practical 
tasks, making participants practice skills such as self-assertiveness, communication and 
problem solving, empowering the participants throughout the program. A psychoeducation 
program avoids the pathogenetic doctor and patient relationship by considering the patients as 
participants in the program rather than patients in the psychoeducational setting (Motlova, 
2017).  
Psychoeducation can be delivered in different formats, to either individuals alone or in 
groups. Individual psychoeducation may be indicated when an anxious person feels 
threatened by group situations or wish to stay confidential about the illness (Psychoeducation: 
Definition, Goals and Methods, 2014). The group format can for some people feel less 
intimidating than one-to-one sessions and the sharing of experiences in groups will benefit the 
participants. Support from group members is key to reducing stress and stigma and to be 
motivated to cope with the disorder (Psychoeducation: Definition, Goals and Methods, 2014). 
Lewinsohn, Hoberman, Teri and Hautzinger, (1985) describe group psychoeducation (GPE) 
as an approach developed from a model considering depression as a product of multiple risk 
factors acting to transform the emotions, actions and cognitive processes of individuals facing 
adverse conditions (as cited in Dowrick, 2001). Cognitive behavioral treatment (CBT) 




incorporated in a structured psychoeducational format for groups (Dowrick, 2001). The most 
common format is the Coping with Depression Course (CWDC) which was developed by 
Lewinsohn and Clarke in 1984 (Efthimiou & Psoma, 2012). The aim of psychoeducation is 
both prevention and treatment, it can be used in combination with drugs and it has been used 
in both health care and community settings (Dowrick, 2001). Group psychoeducation is 
implemented in different countries, such as Germany, the Netherlands, and USA (Haringsma, 
Cuijpers & Spinhoven, 2006). Chile is another example and is one of the few middle-income 
countries that has implemented a national comprehensive multi-component treatment program 
for depression including group psychoeducation, and it has proven to have good results 
(Araya, Alvarado & Minoletti, 2011).  
Group psychoeducation will often involve caregivers such as family and friends. People with 
depression are normally taken care of by a relative in their home. Here, we will use the term 
caregiver, relative and family interchangeably. Group psychoeducation that includes family 
member(s) (FPE) emerged from different sources in the late 1970s (McFarlane, 2016). The 
first model for single-family psychoeducation format was developed by Andersen et al., in 
1986 (Fallon, 1984; Miklowitz & Goldstein, 1997) and the multi-family format (MFPE) was 
introduced in 2002 by McFarlane (MacFarlane, 2016). The format of family psychoeducation 
can be valuable for the whole family. Information and activities may help family members to 
better understand the person suffering from the illness, and it may enable them to give the 
required support, as well as helping the family to get along with one another 
(Psychoeducation: Definition, Goals and Methods, 2014). 
While there are numerous variations of psychoeducational approaches, we have decided to 




• is provided to groups of patients or groups consisting of one or more patient with their 
caregivers (family members, friends or other) 
• is provided by a health care professional 
• includes exercises in practical skills relevant for the patient and family group such as 
coping strategies, behavior, communication, social interactions, and problem solving 
• aims at giving knowledge on depression and treatment of depression 
• is specific for patients with depression 
Modules in psychoeducation are typically designed to cover these elements:  
“(1) Information transfer (symptomatology of the disturbance, causes, treatment 
concepts, etc.); (2) Emotional discharge (understanding to promote exchange of 
experiences with other concerned, contacts, etc.); (3) support of a medical or 
psychotherapeutic treatment, as cooperation is promoted between the mental health 
professional and patient (compliance, adherence); and (4) assistance to self-help (e.g. 
training, so crisis situations are promptly recognised and steps taken to help the 
patient)” (Kumar & Gupta, 2015). 
Psychoeducation can be delivered to the participant in many ways and the mode of delivery 
may be of importance for the effect of the intervention. Psychoeducation can also be delivered 
in multifamily groups, in a consultation given by a healthcare professional on one-to-one 
basis or as a web-based course with no human interaction. We use the term group 
psychoeducation for an intervention involving both participant and caregiver. However, group 





Group psychoeducation may be conducted by health care professionals other than 
psychologist or psychotherapists (Cuijpers, Munoz, Clarke & Lewinsohn, 2009). The 
simplicity of psychoeducation allows training which is neither long nor complex in the 
technique, thus the intervention is not dependent on a specialist (Colomn, 2011). Nurses or 
other health care professionals who are experts on the disorder, rather than a technique, can 
conduct the intervention (Colomn, 2011). 
The most common format of psychoeducation, the CWDC consists of twelve two-hour 
sessions over 8 weeks, and a modified version with 8 sessions (Dowrick, 2001). We have 
included all durations (doses) of group psychoeducation in this review, as long as it is 
minimum one 60-minute session. 
1.5 How the intervention might work   
According to Frances Colom (2011);  
"Psychoeducation could be defined as a patient’s empowering training targeted at 
promoting awareness and proactivity, providing tools to manage, cope and live with a 
chronic condition (i.e. adherence enhancement, early warning sign identification, 
lifestyle, crisis management, communication), and changing behaviors and attitudes 
related to the condition. Psychoeducation replaces guilt by responsibility, helplessness 
by proactive care and denial by awareness" (Colom, 2011).    
The core of the psychoeducation intervention is the didactic element, which is meant to 
provide the participants (patients) with insight into their disease and learn how to accept it and 
cope with it successfully. The content of the psychoeducation course may vary, but it includes 




communication skills and healthy living, amongst other. Motlova et al. (2017), points out four 
active ingredients in psychoeducation: 
1. Taking the whole participant into account and building on the participants strengths 
and resilience  
2. Giving the participant emotional support, guidance and sufficient knowledge to accept 
this reality and adapt to the illness. Including information on how to reduce stress in 
the household.  
3. Psychoeducation must include behavioral interventions, promoting healthy activities 
such as healthy eating, sufficient sleep, exercise and support from friends.   
4. Psychoeducation shall ensure that participant and caregivers have access to reliable 
sources of information to avoid miseducation that may occur form unreliable internet 
sources 
Psychoeducation focuses on improving the functioning of the patients (Murray-Swank & 
Dixon, 2011). The therapeutic mechanism may be due to behavior change, leading to 
interruption of the vicious cycle normally seen in depression, and an improved interaction 
with the environment with a better function as a result of this (Cuijpers, Munoz, Clarke & 
Lewinsohn, 2009). Exploring the effect of family psychoeducation on MDD is timely and 
relevant. Recent research by The Brainstorm Consortium (The Brainstorm Consortium, 
Anttila et.al. 2018) revealed there is a high degree of heritability and a genetic correlation 
between common psychiatric diseases such as major depressive disorder, attention deficit 
hyperactivity disorder, bipolar disorder, and schizophrenia. This means that in a family where 
one family member is suffering from any of these diseases, there may be other family 
members at risk of at least one of the associated diseases. A family intervention may therefore 




importance for all involved parties. Family psychoeducation programs are already considered 
an evidence-based intervention in the treatment of schizophrenia and bipolar disorder 
(Murray-Swank & Dixon, 2005).   
In family psychoeducation, caregivers or family members are regarded as important resources 
for the patient’s health recovery. According to Brandy, Kangas & McGill (2016), the aim of 
FPE is to enhance treatment outcomes by enabling those who are closest to the person, family 
or other caregiver, to assists in events which may exacerbate the illness. Another key element 
of family psychoeducation is what Murray-Swank and Dixon (2005) describe as “expressed 
emotions”. Expressed emotions is referring to the level of criticism and emotional over-
involvement among caregivers in the patient’s environment (Murray-Swank & Dixon, 2005). 
MDD causes high levels of family burden and expressed emotions (Luciano et al., 2012). A 
knowledgeable caregiver may have improved coping skills and better ability to withstand the 
suffering of the depressed family member. 
1.6 Why is it important to do this review?  
Depression causes significant burden to individuals, families, and society, but access to 
psychological therapy for depression is limited, and there is a need to strengthen the evidence-
base on effective psychological treatments. Psychoeducation is one easily accessible approach 
that has proven to be beneficial to patients suffering from psychosis and bipolar affective 
disorder, but there is currently a knowledge gap regarding psychoeducation and major 
depressive disorder (McFarlane, 2016). Studies have shown that family functioning is 
important in determining the course of MDD (Keitner et al., 1995). We believe this 
systematic review on PE involving family members in treatment for MDD can further 




functioning. There is a clear need to reduce the gap between demand and access to treatment 
for depression. If group psychoeducation is proven to be effective compared to other available 
treatment options; it has the potential to play an important role in making treatment accessible 
to a large number of patients in need, worldwide.  
1.7 Review question   
Is group psychoeducation as sole therapy or as an adjunct therapy effective for adults with 
major depressive disorder compared to pharmacological treatment and/or other psychological 
treatments?             
1.8 Objective    
The aim is to systematically review the effectiveness of group psychoeducation for adults 
with major depressive disorder, as sole therapy or in conjunction with treatment as usual, 
compared to pharmacological treatment and/or other psychological treatment. Included effect 
measures are quality of life, depression severity, mortality (suicide), psychosocial 
functioning, relapse, and compliance.  
2 Methods    
We conducted a systematic review in accordance with the Cochrane Handbook for Systematic 
Reviews of Interventions, Version 5.1.0 (Higgins & Green, 2011). This chapter describes the 
methods and choices we made. Our PROSPERO protocol was registered in September 2017 




2.1 Search strategy  
The search strategy was prepared by us in collaboration with a research librarian from the 
Norwegian Institute of Public Health, and peer reviewed by another research librarian from 
the same institution. The search was conducted by the librarian and individually adapted for 
the following databases: 
• MEDLINE (OVID) 
• PsycINFO (OVID) 
• EMBASE (OVID) 
• Cochrane Library (CDSR, HTA, CENTRAL, DARE) 
• CINAHL (EBSCO) 
• Epistemonikos 
The literature search consisted of subject headings and text word-controlled vocabulary, e.g. 
MeSH in MEDLINE, covering depression and psychoeducation. The search was limited to 
year 2000 and newer, because of a consensus that the critical elements of family 
psychoeducation was developed in 1999 (U.S. Department of Health and Human Services, 
2009). The search closed in September 2017. The full search strategy is enclosed in appendix 
2. In addition to the systematic search in electronic databases, we hand searched the reference 
lists of systematic reviews and literature reviews to identify any relevant studies not indexed 
in the databases.  
2.2 Inclusion and exclusion criteria     
The inclusion criteria for effectiveness studies of group psychoeducation for major depressive 




by the question’s different elements below: Study design - Patient – Intervention – 
Comparator – Outcomes (SPICO). 
2.2.1 Study design   
Studies we pre-specified to be eligible for inclusion were randomized controlled  trials (RCTs) 
and non-randomized controlled trials (non-RCTs), controlled before-after studies (CBAs), 
interrupted time series (ITS) plus prospective and retrospective cohort studies with a control 
group. We also specified that in the event of identifying several high-quality RCTs and non-
RCTs, we would consider not including other study designs. Cluster RCTs analysed on an 
individual level should be adjusted for intra cluster correlation (ICC).  
2.2.2 Population  
Eligible participants (patients) were adults with major depressive disorder. Table 1 gives an 
overview of the included ICD-10 codes included in this systematic review. This list of 
specific ICD-10 codes to be included in the review were discussed with a psychiatrist, to 
cover the right diagnostic codes for MDD.  
Studies with more than 50% of patients with medical comorbidities were excluded (e.g. 
anxiety, diabetes, cancer). Other studies excluded were studies with more than 50% of 
patients with Perinatal Depression, Bipolar Affective Disorder and mental impairment, 
including dementia. We excluded studies with patients in remission and who thus no longer 
met the depression criteria. We discussed among us and with a psychiatrist whether the 
exclusion of patients with anxiety was reasonable, as depression and anxiety often go hand in 
hand, and concluded that for this review it was prudent to focus on patients with depression 
only.       
Table 1. Included ICD-10 codes 








An episode of depression in which several of the depressive 
episode (F32) symptoms are marked and distressing, typically 
loss of self-esteem and ideas of worthlessness or guilt. Suicidal 
thoughts and acts are common, and a number of "somatic" 
symptoms are usually present. 
Single episode without psychotic symptoms (agitated 




episode with psychotic 
symptoms 
An episode of depression as described in F32.2, but with the 
presence of hallucinations, delusions, psychomotor retardation, 
or stupor so severe that ordinary social activities are impossible; 
there may be danger to life from suicide, dehydration, or 
starvation. The hallucinations and delusions may or may not be 
mood-congruent. 
Single episodes of: 
• major depression with psychotic symptoms 
• psychogenic depressive psychosis 
• psychotic depression 









A disorder characterized by repeated episodes of depression, the 
current episode being severe without psychotic symptoms, as in 
F32.2, and without any history of mania. 
Endogenous depression without psychotic symptoms 
Major depression, recurrent without psychotic symptoms 
Manic-depressive psychosis, depressed type without psychotic 
symptoms  









A disorder characterized by repeated episodes of depression, the 
current episode being severe with psychotic symptoms, as in 
F32.3, and with no previous episodes of mania. 
Endogenous depression with psychotic symptoms 
Manic-depressive psychosis, depressed type with psychotic 
symptoms 
Recurrent severe episodes of: 
• major depression with psychotic symptoms 
• psychogenic depressive psychosis 
• psychotic depression 
• reactive depressive psychosis 
F34.0  
Cyclothymia 
A persistent instability of mood involving numerous periods of 
depression and mild elation, none of which is sufficiently severe 
or prolonged to justify a diagnosis of bipolar affective disorder 
(F31.-) or recurrent depressive disorder (F33.-). This disorder is 
frequently found in the relatives of patients with bipolar 
affective disorder. Some patients with cyclothymia eventually 
develop bipolar affective disorder. 










A chronic depression of mood, lasting at least several years, 
which is not sufficiently severe, or in which individual episodes 
are not sufficiently prolonged, to justify a diagnosis of severe, 
moderate, or mild recurrent depressive disorder (F33.-). 
Depressive (neurosis, personality disorder) 
Neurotic depression 
 
Persistent anxiety depression 
Excl.: anxiety depression (mild or not persistent) (F41.2) 
 
 
2.2.3 Intervention  
The intervention was group psychoeducation that had the following characteristics 
(McFarlane, 2016): 
• Is provided to groups of patients or groups consisting of one or more patient with the 
caregivers (family members, friends or other) 
• Is provided by a health care professional 
• Includes exercises in practical skills relevant for the patient and family group such as 
coping strategies, behavior, communication, social interactions, and problem solving 
• Aims at giving knowledge on depression and treatment of depression 
• Is specific for patients with depression     
We included all durations (doses) of group psychoeducation as long as the intervention 
consisted of minimum one 60-minute session. Group psychoeducation could be given as sole 
treatment or in conjunction with treatment as usual (TAU).    
2.2.4 Comparison   
 We specified the following comparison conditions: 
• Antidepressant medications. We limited medication to be common antidepressants 




• Other psychological intervention (psychological interventions in the Cochrane 
CCDAN list of 87 interventions were included. See Cochrane CCDAN, n.d.) 
2.2.5 Outcomes 
We specified the following primary outcomes: depression severity, quality of life, and 
mortality (suicide). The secondary outcomes were level of psychosocial functioning, relapse, 
and treatment adherence. 
Measurement tools for the outcomes are described in chapter 3.2.6. 
2.3 Selection of literature  
Two reviewers (ÅR and HS) screened independently of each other all the abstracts from the 
literature searches by the use of Rayyan QCRI – a web and mobile app for systematic reviews 













We promoted all relevant abstracts to full text examination, and again independently assessed 
the studies’ relevance relative to the inclusion criteria. The search retrieved both primary 
studies and systematic reviews. We hand searched the reference lists of the systematic 
reviews for any relevant primary studies which were not identified through the database 
searches. Any disagreement about relevance of primary studies was solved by discussion with 
a third researcher (RB). We present excluded studies read in full text, with the reason for 
exclusion, in appendix 3. Ongoing studies with a protocol published are described in appendix 
4.        
2.4 Assessment of methodological quality (Risk of bias 
assessment)  
The two reviewers, HS and ÅR, first independently and then together performed an 




assessed the risk of bias for all studies according to the criteria for RCTs in the Cochrane 
Handbook for Systematic Reviews of Interventions (Higgins & Green, 2011). We evaluated 
the processes for sequence generation; allocation concealment; blinding of participants and 
personnel; blinding of outcome assessment; incomplete outcome data; selective outcome 
reporting; and other sources of bias. The risk of bias for all processes are reported as ‘Low 
Risk’, ‘Unclear Risk’, or ‘High Risk’.  When there is no cause for concern the procedure is 
considered to have low risk of bias. When there may be a risk of bias, but there is either 
insufficient information to assess whether an important risk of bias exists or there is 
insufficient rationale or evidence that an identified problem will introduce bias, we assigned 
unclear risk of bias. Procedures with cause for concern is assigned high risk of bias. Any 
disagreement regarding risk of bias was solved by discussion between the two reviewers and 
with some guidance from the supervisor. The full risk of bias assessment of included studies 
is enclosed in appendix 5. If study designs other than RCT were to be included, we would 
have use the procedures described in the protocol in appendix 1. 
2.5 Extraction of data   
We created a standard data extraction form. Both reviewers extracted data from all included 
studies by using the data extraction form. We then compared the extractions to ensure all 
correct and necessary data were extracted. The information we extracted was: title, authors 
and other publication details, study design and aim, setting (place and time of 
recruitment/data collection), sample characteristics (age, gender, etc.), intervention and 
control characteristics (duration/dose, provider, content, etc.), methods of outcome 
measurement (instruments/ tools), results/outcomes. The mapping of the outcomes per study 




2.6 Data analysis              
In statistical analyses we are seeking differences that are not random. A significant result 
means that we have chosen a level (95%) for how sure we want to be about the results not 
being random. The significance can be measured by using p-values or confidence intervals 
(CI).  
Our research question is about effect of an intervention. In systematic reviews it is the effect 
at group level which will be examined in the analysis, meaning it is the mean effect in the 
group we are considering. The effect value can be calculated in different ways.  
Risk ratio (RR) is generally used for dichotomous outcomes. The effect measure is then the 
ratio between the probability that an event occurs in both groups. If the probability is equal in 
the two groups, the risk ratio will be 1. A risk ratio of 2 means that the probability that an 
event occurs is twice as big in the intervention group compared to the control group. For 
continuous data, the effect measure is mean difference (MD) or standardized mean difference 
(SMD). We have used 95% confidence intervals (95% CI) to calculate the effect sizes by 
using the RevMan tool (Review Manager, 2014). MD for continuous outcomes applies when 
the same measurement scales are used. The effect measure is then the absolute difference 
between the mean value in the two groups, and it estimates the amount by which the 
experimental intervention changes the outcome on average compared with the control 
(Higgins & Green, 2011). 
If studies were sufficiently similar with respect to population, intervention, comparison and 
outcome, we decided we would conduct meta-analyses, using the RevMan tool, and generate 




If we pooled studies with continuous outcomes and the studies did not use the same 
measurement instrument, we would recalculate all results into standardized measures and get 
the SMD. 
There will almost always be some heterogeneity between estimates that are pooled. 
Heterogeneity can be clinical (differences between the participants, the interventions or 
outcomes), methodological (differences in study design or in risk of bias) or statistical 
(Higgins & Green, 2011). We define heterogeneity when there is great variation in results, 
non-overlapping CIs, P<0,001 and I>50% (Higgins and Green, 2011). We examined causes 
for and attempted to explain heterogeneity. 
Meta-analyses can be conducted with either a random effects model or a fixed effects model. 
We selected to use a random effects model to combine the effect estimates, rather than a fixed 
effects model, because we judge there might be systematic differences between the studies 
while a fixed-effect model would consider each individual study as part of one big study 
(Higgins & Green, 2011). 
For the effect comparisons where there was only one study, or studies could not be pooled, 
we presented the results narratively in text and tables. 
When there are many studies included in a meta-analysis and high heterogeneity, it is possible 
to conduct sub-group analyses, meaning that studies are grouped to check if there are 
significant differences between the groups. We pre-specified the following sub-groups or 
subsets that we would examine: 
• Effect of group composition: groups consisting of patients only or patients together 




• Dose effect of the psychoeducation therapy: 12 sessions (of 1-2 hours duration every 
week) or less were considered low dose, 13-52 sessions (of 1-2 hours duration every 
week) were considered moderate dose, and 52 sessions and above (1-2 hours duration 
every week) were considered high dose (Xia, Merinder & Belgamwar, 2011). 
In our review, it was possible to elaborate the effect of group psychoeducation with a sub-
group analysis investigating family psychoeducation, grouping studies with participants 
together with their caregivers (family psychoeducation) compared to studies with groups for 
patients only.  
2.7 Assessment of the certainty of the evidence (GRADE) 
Grading of Recommendations Assessment, Development and Evaluation (GRADE) 
methodology was used to consider the certainty of the evidence (The Grade Working Group, 
2013). The two reviewers (HS and ÅR) conducted the grading together. We used the standard 
definitions to assess the certainty of the evidence, with the certainty of the evidence classified 
as either high, moderate, low or very low. The different levels of certainty of evidence reflects 
the extent to which we are confident that an estimate of the effect is ‘correct’. The certainty of 
the evidence is rated for each outcome across studies (i.e. for a body of evidence). 
 
 
Table 2: Grades of certainty of evidence 
Grade Symbol Definition 
High  We are very confident that the true effect lies close to that of the 
estimate of the effect 
Moderate  We are moderately confident in the effect estimate: The true effect is 
likely to be close to the estimate of the effect, but there is a possibility 
that it is substantially different 
Low  Our confidence in the effect estimate is limited: The true effect may be 
substantially different from the estimate of the effect 
Very low  We have very little confidence in the effect estimate: The true effect is 





The study design is the starting point for the grade assessment. Randomized controlled trials 
are considered to start as high and observational studies are considered to start as low. Factors 
that can lower the certainty of evidence according to The Grade Working Group (2013): 




• Publication bias 
Factors that can raise the certainty of evidence: 
• Large magnitude of effect 
• Dose response relationship 
• Opposing bias & confounders 
The decision to up rate certainty of evidence is only made for observational studies and only 
when serious limitations in any of the 5 areas reducing the certainty of evidence is absent. 
2.8 Changes from the original protocol 
To improve precision, we made a small change in the research question. The original question 
as registered in PROSPERO was: “Is group psychoeducation effective in improving quality of 
life in adults with major depressive disorder compared to pharmacological treatment and/or 
other psychological treatment?” We amended the research question to: “Is group 
psychoeducation, as sole therapy or as adjunct therapy, effective for adults with major 
depressive disorder compared to pharmacological treatment and/or other psychological 




When planning the review, as shown in our PROSPERO registered protocol, we focused on 
comparing the effect of group psychoeducation with pharmacological interventions and/or 
other psychological interventions. It rapidly became evident that most patients given 
psychoeducation continue to receive treatment as usual (TAU), such as psychotherapy and 
pharmacological treatment. While none of the studies excluded TAU not all patients used all 
available treatment alternatives. Thus, it was obvious that we would include studies regardless 
of whether psychoeducation was given as sole treatment or in conjunction with other standard 
treatment. TAU varies across settings and here it was defined as access to health care 
professionals and access to pharmacological medication (see table 7 for details on TAU).         
3 Results   
3.1 Results of the literature search    
The search in electronic databases gave 4215 references in total after deletion of duplicates 
(figure 2). We hand searched 29 systematic reviews for relevant references, which yielded 
four additional articles, giving a total of 4219 references. We excluded 4167 records based on 
title and abstract and read 52 full text articles. One author (Conradi, Jonge & Ormel, 2008) 
was contacted by e-mail to clarify whether the study in question met our inclusion criteria, it 
did not, and one author (Lara, Navarro & Mondragon, 2003) was contacted in an attempt to 
retrieve numeric results of the study. Both of these studies are listed among the excluded 
articles read in full text (appendix 3). We identified three study protocols (see appendix 4). At 
the end of our selection process, nine RCTs matched our inclusion criteria and other study 
designs were thus not considered, as per our protocol.   






3.2 Description of included studies and their context  
Nine unique studies presented in 10 articles are included in this systematic review. The 
earliest study is from year 2000 and the most recent study is from 2017. Studies include 
psychoeducation delivered in three different ways; in groups of patients, as a brochure handed 
to the patient, and in groups including participants and their caregivers (family 
psychoeducation). Günadyɩn & Barlas (2017) had one study arm delivering psychoeducation 
as a brochure.  This intervention did not meet our inclusion criteria, and the participants 
receiving this intervention are not included in any of the analysis. Dowrick et al (2000) had 
one study arm receiving problem solving, participants in this arm was also excluded from the 
analyses.    
References identified via 
database searches, after 
deletion of duplicates 
n=4215 
Other references 






based on title and 
abstract 
n=4167 










The included studies were conducted on four different continents (Africa, America, Asia, and 
Europe) and in 11 different countries (Denmark, Finland, India, Iran, Norway, Republic of 
Ireland, Spain, South Africa, Turkey, United Kingdom, and USA). One study (Dowrick et al., 
2000), was conducted in multiple countries (Finland, Norway, Republic of Ireland, Spain and 
United Kingdom). The total number of individual research participants in the included studies 
is 1231. The results of one study (Dalgard, 2006) are provided in two articles (Dalgard, 2004 
and Dalgard, 2006), one of which is only published in Norwegian (Dalgard, 2004). This study 
is referred to as Dalgard 2006 in tables throughout this review. The cultural, sociological and 
economic contexts vary greatly among the studies and the baseline treatment for depression 
(treatment as usual) must be interpreted for each study. Chetty and Hoque (2013) described 
their study as “quasi-experimental” and Sharif, Ashkani and Zoladl (2012) called their study 
“interventional case control study”. However, based on the descriptions, it is clear that both of 







Table 3. Brief overview of the included studies (N=9) 
 
Study & context  Population  Intervention: GPE Comparator  Outcome  







8 weekly sessions of 
120 minutes 
Group consisting of 
patients + 1 session with 
caregiver  
TAU  
TAU  Decline in BDI   
Drop-out/non-
compliance, 
psychotropic drugs and 
social measurement 
Admission to psychiatric 
hospital 
Casañas 2012  
Spain, Barcelona 
N= 231  
MDD according to 
ICD-10 Depressive 
Disorder 
BDI 10-29 (mild or 
moderate)   
12 weekly sessions, 90 
minutes  
Group consisting of 
patients 
TAU  
TAU  Remission (BDI <11)  










to DSM 4   
 
BDI 10-28 (mild to 
moderate)  
15 weekly sessions, 60-
120 minutes  
Group consisting of 
patients  
TAU  
TAU  Depressive symptoms 
(BDI)  
Cohen 2010  
 
USA, Long Island  
N=35  
MDD and 
Dysthymia,   
BDI-2 >21   
5 weekly sessions of 
120 minutes,  







(BDI-2, HAM-D)  
Spouse impact: (FSDS)  
Change of behavioural 
and attitude (IRBAS)  
Overall relationship 
satisfaction (DAS)  











depression)   
8 weekly sessions, 150 
minutes, plus booster 
sessions 1, 2 and 4 
months after the course 







Dowrick 2000  
Finland, Norway, 
Republic of Ireland, 
Spain, United 
Kingdom  





12 sessions, 2 hours 
over 8 weeks,  
Group consisting of 
patients   
TAU   
Comparator I  
TAU 
Comparator II  
Problem solving  
TAU 





Quality of life (SF-36)  




Legend: N= number of participants, TAU= treatment as usual,  ICD-10= 10th International Statistical 
Classification of Diseases and Related Health Problems. 
 
3.2.1 Study setting 
The studies were conducted in a variety of settings (table 4). All of the studies were 
conducted in urban areas except for the multicentre study by Dowrick et al. (2000), that 
reported urban and rural settings, without any further information. Patients were recruited as 
primary patients (Aagaard, Foldanger, Makki, Hansen & Muller-Nielsen, 2017, Casañas, 
Catalan, del Val, Real, Valero & Casas, 2012, Chetty & Hoque, 2013) as referral patients 
(Günadyɩn & Barlas, 2017; Kumar & Gupta, 2015, Sharif & Ashkani & Zoladl, 2012), by 
using mass media (Dalgard, 2006 and Cohen, O’Leary & Foran, 2010) or by a process 
described as a “two stage community survey” (Dowrick et al., 2000). 
Two studies were pre-registered in Clinical Trials.gov (Casañas et al., 2012 and Dalgard, 
2006). However, one of these (Dalgard, 2006), was not pre-registered, but registered just 
before publication of the article providing the results. Informed consent was reported to be 
obtained in six studies (Aagaard et al., 2017; Casañas et al., 2012; Chetty & Hoque, 2013; 
Study & context Population  Intervention  Comparator  Outcome 
 









BDI score 17-30  
    
5 weekly sessions of 45-
60 minutes 
Group consisting of 
patients   
TAU   
Comparator I  
TAU   
Comparator II  
Psychoeducation 













   
Sessions on week 0, 
week 2, week 4 and 
week 8  
Group consisting of 
caregiver and patients 
TAU  
TAU  Depressive symptoms 
(HAM-D)  
Quality of life (PGWBI) 
Psychosocial functioning 
(GAF)   





to ICD-10 criteria  
  
6 weekly sessions of 90 
minutes duration.  
Group consisting of 6 
patients  
TAU 
TAU  Quality of life  





Günadyɩn & Barlas, 2017; Kumar & Gupta, 2015; Sharif & Ashkani & Zoladl, 2012) and 
ethical approval by a board is reported in four studies (Aagaard et al., 2017, Casañas et al., 
2012, Chetty & Hoque, 2013, Sharif & Ashkani & Zoladl, 2012). In the studies by Cohen, 
O’Leary & Foran, 2010, Dalgard, 2006, and Dowrick et al., 2000, there was no information 
about informed consent. 




Setting Ethical approval/registration 
Aagaard 2017  
Denmark  
 
Multicentre study conducted in 4 
different Community Mental Health-
Centres 
Urban 
Written informed consent obtained from 
patient 
Approval from the Danish Data Protection 
Agency and the Scientific Ethic Committee. 
Casañas 2012  
Spain, Barcelona  
Participants recruited at Primary 
Care Centres 
Urban 
Informed consent was obtained from all 
participants 
Ethical approval by the Gol Guriana 
Foundation. 
Clinical Trials.gov NCT00841737 
Chetty 2013  
South Africa,  
southern 
KwaZulu-Natal   
Participants recruited at Urban-
community-psychiatric-clinic  
Urban 
Informed consent was obtained from all 
participants  
Ethical permission was obtained from the 
Research, Publication and Ethics Committee 
of the Durban University of Technology  
Cohen 2010  
USA, Long 
Island   
Participants recruited using TV, radio 
announcements, flyers and pamphlets in 
local medical clinics 
Urban 
 No information available  
  
Dalgard 2006  
Norway, Oslo 
Participants recruited using newspaper 
advertisement  
Urban 
 No information available 
Clinical Trials.gov NCT00319540 






Kingdom   
Participants recruited “…by a two stage 
community survey…”  
Urban and rural 
No information available 
Günadyɩn 2017  
Turkey, Istanbul 
  
 “The research universe was composed 
of entire patients applied to psychiatric 
polyclinic of a state hospital in a month 
and diagnosed with depression…” 
Urban  
Informed consent was obtained from all 
participants 
Ethical approval was obtained according to 
The Code of Ethics of the World Medical 
Association 
Kumar 2015  
India, New Delhi 
  
Recruitment: “The study was conducted 
at the Department of Psychiatry of 





Vardhman Mahavir Medical College & 
Safdarjung Hospital…” 
Urban 
Sharif 2012  
Iran, Shiraz 
  
Recruitment: “They were admitted in the 
psychiatric units of hospitals affiliated to 
Shiraz University of Medical Sciences at 
the time of study” 
Urban   
Written informed consent was obtained from 
all participants 
Approval by the Ethics Committee of Shiraz 
University of Medical Sciences was obtained 
 
3.2.2.  Study population 
Worldwide, there are more women than men who suffer from depression (WHO, 2018). This 
is seen in the samples in this review. The study by Kumar & Gupta (2015) is the only study 
where the majority of the patients are male. In this study the majority of caregiver are also 
male. Two studies (Chetty & Hoque, 2013 and Cohen, O’Leary & Foran, 2010) included 
female participants only (table 5). 
With regard to age, the mean ages across the studies was 33-54. One study (Kumar & Gupta, 
2015) included participants from 15 years to 59 years. This study was conducted in New 
Delhi, India. The average age in this particular study was 36.17 years (SD ±11). While we 
specified that we would only include populations 18 years or older, the number of participants 
under 18 in this study is negligible, thus we decided to include the study. We also believe that 
the age at which the society defines the commencement of adulthood varies between cultures 
and that Indian adolescent are considered adults at an earlier age than in many other societies. 
This may be expressed in the high rate of child marriages in India, where 27% of 20 to 24-
year olds was married before the age of 18, in the years between 2010 and 2017 (UNICEF, 
2018). The study was included in this systematic review because it seemingly had few, if any, 
underage participants and if any underage participants was included, they had probably 




All participants suffered from MDD. The severity of depression of the participants (mild, 
moderate, severe) varied among the studies, see table 5 for details. 
Table 5. Overview of the population in the included studies 
Study   No of participants  
% female  
Comment 
Age Diagnostic criteria 
Aagaard 2017 N=80  
71% females  
Mean age=48  ICD-10 recurrent depression 
Casañas 2012 N=231  
89% females  
Age> 20  
Mean age=53.8  
Major Depressive Disorder (MDD) 
according to ICD-10 Depressive Disorder  
BDI 10-29 (mild or moderate).  
Chetty 2013   N=30   
100% females  
Indian South African 
women 
Age range 31-60 
years 
Mean age=45.2   
Depressed according to DSM 4   
BDI 10-28 (mild to moderate)  
Cohen 2010   N=35  
100% females  
(100% male 
caregiver) 
Mean age=43.74   MDD and Dysthymia  
BDI-2 >21  
Dalgard 2006   N=155 
76% females   
Mean age=50.3   Unipolar depression according to DSM-
4   
BDI mean= 21.8/22.9 (moderate 
depression) Depressive symptoms  
Dowrick 2000   N=425   
65% females   
Age 18-65 years   Depressive episode according to ICD-10 
Günadyɩn 2017    N=153   
92% female   
Age range 18-65 
years   
Unipolar depression, DSM-IV   
BDI score 17-30  
Kumar 2015   N=80  
38.8% female  
(57% male caregiver) 
Age range 15-59 
years  
Mean age= 33 years 
Unipolar depression, MDD to dysthymia, 
according to ICD-10 criteria  
Sharif 2012   N=60  
54.9% female  
Age >18 years   MDD according to ICD-10 criteria  
 
3.2.3 Intervention 
The psychoeducation intervention in the included studies all have a didactic element, 
providing knowledge on depression, medication, and various other aspects. Several of the 
didactic programmes are based on a pre-defined syllabus such as “Group Psychoeducation 
Programme” (Aagaard et al., 2017), “Women’s Workbook and Facilitator`s Manual” (Chetty 
& Hoque, 2013), “Coping with depression course” (Dowrick et al., 2000) and “Continuity 




Eight of nine studies provided a low dose of intervention, that is, less than 12 sessions of 
minimum 1 to 2 hours, according to our definition. The ‘dose’ of psychoeducation given to 
the intervention group varied from 4 sessions over 8 weeks, giving the lowest dose (Kumar & 
Gupta, 2015), to 15 weekly sessions of 1-2 hours, representing the highest dose (Chetty & 
Hoque, 2013). Thus, this latter study (Chetty & Hoque, 2013) had a moderate dose of 
intervention. One study (Dalgard, 2006) had booster sessions: one, two and four months after 
the end of the psychoeducation course, giving a total dose of 11 sessions. Time of the final 
assessment varied between 10 weeks and 52 months after randomization. 
 
Two studies included caregivers in the group psychoeducation (Cohen, O’Leary & Foran, 
2010 and Kumar & Gupta, 2015) and we therefore regarded these interventions as family 
group psychoeducation. While, Aagaard et al. (2017) had caregiver included in one session, 
but we did not categorize this study as family group psychoeducation because the majority of 
the intervention was provided in a patient group setting. Figure 3 gives an overview of the 














Figure 3. Overview of types of psychoeducation provided in the included studies  
 
 
Nurses seem to play a prominent role in the delivery of GPE interventions. In four of the 
included studies, nurses conducted the intervention alone or in combination with other 
professionals (Casañas et al., 2012, Chetty & Hoque, 2013, Dalgard, 2006 and Dowrick et al., 
2000). A clinician was the facilitator in one study (Cohen, O’Leary & Foran, 2010) and the 
researcher in another (Kumar & Gupta, 2015). Two studies do not provide information on the 
facilitator of the intervention (Günadyɩn & Barlas, 2017 and Sharif & Ashkani & Zoladl, 
2012). Since the studies was conducted in a hospital setting assume that the facilitator of the 
intervention had relevant professional background.  Table 6 gives an overview of the 








Table 6. Overview of the intervention in the included studies 
Study  Description of intervention Dose  Facilitator 
Aagaard 2017  
 
Group Psychoeducation Programme 
(PEP) covering depressive disease, 
psychopharmacological treatment, 
depression and anxiety, impact of 
depression on family and work, and coping 
competence to the disease. Homework was 
considered an important component of the 
programme- 
Group composition: 6-8 patients and two 
conductors 
A caregiver was present in one session  
8 weekly sessions of 
120 minutes 
Highly experienced 
group therapist or 
therapists under 
training 
Casañas 2012  Group Psychoeducation including 
education on health education, diet, 
physical exercise, sleep, pharmacological 
treatment, breathing techniques, problem 
solving, behavioral activation, cognitive 
behavioral perspective on depression, self-
esteem, self-image, pleasant activities, 
social skills and assertiveness. 
Group composition: 8-12 patients and 2 
nurses 
12 weekly sessions, 90 
minutes 
Primary care centre 
nurse 
Chetty 2013   Nurse-facilitated-cognitive-group (FCG) 
intervention based on Verona Gordon`s 
(1988) Women’s Workbook and 
Facilitator`s Manual. Goal- setting, 
depression, self-worth, relationships, 
assertiveness, conflict-management, stress, 
nutrition and exercise are topics that were 
covered.  
Group composition: 5-15 patients and 2 
psychiatric nurses 




Cohen 2010  
 
Family psychoeducation for couples 
where the women was depressed  
Group composition; patient and caregiver 
in group with a clinician   
5 weekly sessions of 
120 minutes 
Clinician 
Dalgard 2006  
  
Group Psychoeducation didactic course 
aiming at promoting positive thinking, 
pleasant activities, social skills and social 
8 weekly sessions of 
2.5 hours, plus booster 
sessions 1,2 and 4 







support. Homework was considered an 
important component of the programme 




Dowrick 2000  
  
Intervention I: Group psychoeducation. 
A modified version of “coping with 
depression course” with emphasis on social 
support was provided to the allocated 
participants  
Group composition: patients and facilitator 
Intervention II: Problem-Solving 
treatment was given to the patient on a 
one to one basis usually in the patient’s 
home    
Intervention I:  
12 sessions of 2 hours, 






6 individual sessions 
providing less than 4 





or allied health 
professions 
  
Günadyɩn 2017  Intervention I: Group psychoeducation 
based on CETA including sessions on 
relationship, attitude, depression 
recognition, compliance, side effects, 
cognitive- behavioral techniques were also 
employed in the course. A large bulk of the 
course is focused on compliance of 
medication.   
Group composition: 8 patients and 
conductor 
Intervention II: Brochure 
psychoeducation, CETA program 
delivered on an individual basis as a 
brochure intervention 
Intervention I:  
5 weekly sessions of 






Intervention II:  
Dose not specified  
Psychiatric nurse 
Kumar 2015  
  
Family psychoeducation covering cause 
of depression, trigger factors, stigma, 
pharmacotherapy, suicide, expressed 
emotion, caregiver burden outcome, 
quality of life, problem-solving, forming 
an action plan, and more.  
Group composition: patient, caregiver and 
researcher 
4 sessions held on 
week 0, week 2, week 
4 and week 8  
 
Researcher 
Sharif 2012  
  
  
Group psychoeducation covering 
depression, signs and symptoms, 
medication, treatment, side effect of 
medication, self-esteem, assertiveness, 
negative thought patterns, rational 
thinking, social skills training and 
relaxation.   
Group composition: 6 patients and 
conductor 








3.2.4 Control and treatment as usual  
The nine included studies have various descriptions of the basic healthcare provided to all 
patients, whether they were in the intervention or the control group, and many of the studies 
have especially scarce information about care provided to the control group. However, our 
reading and interpretation of the studies are that all participants had access to basic healthcare 
for MDD, such as access to healthcare professionals and access to antidepressant medication. 
It would be considered unethical to conduct a study where participants diagnosed with MDD 
were deprived of all traditional treatments for depression. Hence, all participants seem to have 
had access to basic level of care for their MDD. This can be considered treatment as usual 
(TAU). While we did not apply the term "treatment as usual" in our review protocol, the 
treatments nonetheless fit our description of included comparisons. We note however that the 
description of the basic level of care must be interpreted from the description given in each 
publication and from the social context of each study (see table 7). In this systematic review, 
we label the basic level of care, provided to all patients, “treatment as usual” and define this 
term as having access to antidepressant medication and access to a healthcare professional. In 
some of the included studies, "treatment as usual" (TAU) also includes access to 
psychotherapy and other available treatments.    
Table 7. Overview of level of baseline healthcare provided to all patients 
 
Study Description of baseline treatment of 
depression provided to all patients 
(TAU) 
Interpretation of level of baseline care 
(TAU) 
Aagaard 2017  
  
“…2-year outpatient follow-up at a 
CMHC”   
The study was conducted in Denmark.   
The Danish population has readily 
access to high quality healthcare, such as 




52.4% of the intervention group and 36.8 % 
of the control group intervention received 
traditional antidepressant medication.  
Some of the participants used mood 
stabilising medication (19.0% / 31.6%), 
antipsychotic medication (14.3% / 18.4%), 
anxiolytic and hypnotic medication (11.9% 
/ 13.2 %)  
medication. We assume all participants 
had access to excellent healthcare.   
Casañas 2012  
  
“Members of the control group received 
usual treatment (visits to GP and nurses). 
There was no pattern of visits established; 
the patients could go to the primary care 
centre”    
55% the intervention group and 45% of the 
control group received antidepressant 
medication.     
Some of the participants also used hypnotic 
medication (4.8%), anxiolytics medication 
(54.3%), blood pressure medication 
(30.3%) and alternative treatment (22.1%).  
The study was conducted in Barcelona, 
Spain. 
The participants had readily access to a 
general practitioner or a nurse and access 
to antidepressant medication.     
Chetty 2013  
  
“…participants were assessed by a 
psychiatric nurse on a monthly basis or by 
psychiatric clinic doctor if a script needed 
to be reviewed or if the patient had 
problems requiring the doctor’s attention 
and had to collect antidepressant 
medication from the clinic pharmacy.”  
100% of participants used antidepressant 
medication  
The participants were recruited from a 
public, community, psychiatric clinic, 
serviced by the KwaZulu-Natal 
Provincial Health Services in South 
Africa. All participants had regular 
access to a psychiatric nurse or a doctor 
and all received antidepressant 
medication.   
Cohen 2010  
  
“Couples assigned to the waiting list group 
were assessed approximately 5 weeks after 
entry into the study and again three months 
later”  
“Female partners were not restricted from 
receiving concurrent treatments for their 
depression as long as they had been in 
individual psychotherapy for a minimum of 
12 weeks or taking a stable dose of 
psychotropic medication for a minimum of 
8 weeks”   
The study is set in Long Island, USA and 
the majority of the spouses are employed 
we therefore assume that the participants 
had access to healthcare professionals 
and antidepressant medication.    
Dalgard 2006  
  
“The control group as well as the 
intervention group were free to continue 
eventual ongoing treatment (i.e. “treatment 
as usual”).”  
44.4% of participants in the intervention 
group and 42.7 % in the control group used 
The study was conducted in Norway.   
The Norwegian population have readily 
access to high quality healthcare, such as 





medication at time of screening.  24% of 
the intervention group and 12% in the 
control group received psychotherapy at 
time of screening.  
Dowrick 2000  
  
“…controls receiving no treatment.”  
"…(26%) reported concurrently taking 
antidepressants. There were 
no significant differences in diagnosis or 
antidepressant receipt between the study 
sites or intervention arm."  
The study was conducted 
with participants in several countries 
(Finland, Norway, Republic of Ireland, 
Spain, United Kingdom) all of which 
have high quality healthcare readily 
available to the population. We assume 
all participants had access antidepressant 
medication and healthcare professionals  
Günadyɩn 2017  
  
“… the patients who met the inclusion 
criteria were divided into experimental 
((psychoeducation (n=49), brochure 
(n=51)) and control (medication (n=53)) 
group. The psychoeducation group 
(experimental group1) both received group 
psychoeducation (usual care+CETA; 
Continuity Enhancement Therapy for 
Antidepressants) in five sessions and 
antidepressant treatment. The brochure 
group (experimental group 2) both received 
CETA with a brochure and antidepressant 
treatment. The medication (control group) 
group did not receive any psychoeducation 
about depression, antidepressants and only 
continued antidepressant treatments that 
were given by their psychiatrist”   
"….... treatment plan have included that 
antidepressants and have the antidepressant 
treatment for the first time."  
100% of participants used antidepressant 
medication  
The participants in this study are 
recruited through a state hospital 
psychiatric polyclinic in Istanbul. Ethical 
consideration was obtained from a 
multicentre research ethics committee 
and from a public hospital, in accordance 
with Declaration of Helsinki. We 
therefore assume that the term “usual 
care” involves access to healthcare 
professionals.  
 
Kumar 2015  
  
  
“As the study was designed to evaluate the 
role of psychoeducation, the treating 
clinician was absolutely free to continue 
the treatment of his/her own choice.  Both 
groups also received the routine 
unstructured counselling.”  
The study was conducted in Safdarjung 
Hospital, New Delhi, India 
The participants in this study had access 
to antidepressant medication and 
healthcare professionals.   
Sharif 2012  
  
“They were admitted to Shiraz University 
of Medical Sciences at the time of study 
and were on antidepressant medication.” 
“The control group did not receive the 
intervention”  
100% of participants used antidepressant 
medication  
The participants in this study were 
recruited from two hospitals in Shiraz, 
Iran and the study were approved by 
Ethics Committee of Shiraz University 
of Medical Sciences. We therefore 
assume that the hospital provided access 
to healthcare professionals for all 
participants.  Antidepressant medication 







3.2.5 Comparisons and number of studies for each comparison 
Table 8 gives an overview of comparisons included and number of studies in each 
comparison. Our protocol outlines that we should do sub-analyses for FGPE and for dose of 
psychoeducation if possible. Sub-group analyses were performed to examine the effect of 
FGPE, but it was not possible to do sub-group analyses on dose, because all but one study 
provided a low dose of the intervention. The following three meta-analyses were performed 
on the reported outcomes from the included studies; 
• Effect of GPE and TAU vs TAU  
o Subgroup analysis: Effect of FGPE in conjunction with TAU vs patient group 
psychoeducation in conjunction with TAU 
• Effect of FGPE in conjunction with TAU versus TAU  






Table 8. Comparisons and studies included  
Main comparison    Number of studies 
(Study) 
Group psychoeducation and TAU 
vs TAU   
9  
(Aagaard 2017, Casañas 2012, Chetty 2013, Cohen 2009, Dalgard 
2006, Dowrick 2000, Günadyɩn 2017, Kumar 2015, Sharif 2012)  
Sub-group comparison Number of studies 
(Study) 
Family group psychoeducation 
and TAU vs patient group psycho 
education and TAU  
4 
(Casañas 2012,Cohen 2009, Günadyɩn 2017, Kumar 2015,) 
 
3.2.6 Reported outcomes  
Primary outcomes: Quality of life was reported in three studies; (Casañas et al., 2012, 
Dowrick et al., 2000 and Sharif, Nourian, Ashkani & Zoladl, 2012), using 2 different tools 
(EQ-5D and FS-36). Depression severity was reported in 8 studies using 2 different tools 
(BDI and HAM-D). None of the nine studies included had any patients lost to suicide.  
Secondary outcomes: Level of psychosocial functioning was reported in 2 studies, (Cohen, 
O’Leary & Foran, 2010 and Kumar & Gupta, 2015) using two different tools (IRBAS, GAF). 
Relapse (readmittance) was reported in one study (Aagaard et al., 2017). Adherence to 
treatment was indirectly addressed in two studies. It was reported as drop-outs by Aagaard et 
al. (2017) who concluded that belonging to the control group was a significant contributor to 
the drop outs / non-compliance rate. Cohen, O’Leary and Foran (2010), reported on change in 
compliance of medication and concluded there was no difference in medication adherence 
between the two groups. Neither of these two studies directly looked at treatment adherence, 




Several tools are available to assess depression, quality of life and level of psychosocial 
functioning (Wei, McGrath, Hayden, Kutcher, 2016). Table 9 presents the tools used for 
measuring the outcomes of interest in this review.  
Sharif, Nourian, Ashkani & Zoladl (2012) reported the FS-36 outcome in an unrecognisable 
format with some results being out of scale. In this study the self-report tool used to measure 
quality of life, (FS-36) was completed by a researcher and not by the participant. We 
contacted an expert at https://www.optum.com for advice on interpretation of these results 
(Bjørner, J. B. personal communication July 2018) and was advised to exclude the results 
from further analysis, which we did.  
FS-36 results from Dowrick et al. (2000) was reported in several subgroups without a 
summarised total effect and could hence not be included in a meta-analysis with EQ-5D 






Table 9. Description of tools used for measuring the outcomes in the included studies 
Tool  Study  Outcome measured  Description of tool * 
Beck Depression 
Inventory (BDI)  
Aagaard 2017  
Casañas 2012 
Chetty 2013 
Cohen 2010  
Dalgard 2006  
Dowrick 2000  
Günadyɩn 2017
  
Level of depression   21-item self-report tool measuring 
depressive symptoms. Several versions of 
BDI are available (Cohen et al., 2009).     
BDI-II: Sensitivity:  81%  
Specificity:  92%  




(HAM-D)   
Cohen 2010  
Kumar 2015  
Level of depression  21-item reporting scale for measuring 
depression.  Should be administered by a 
clinician experienced in psychology.  
Several versions of the HAM-D 
are available.   
Sensitivity:  86.4%  
Specificity:  92.2%  
(Strik, J.J., Honig, A., Lousberg, R. & 
Denollet J. 2001) 
EQ-5D  Casañas 2012  Quality of life  
(Health Status)  
Self-report tool (Herdman et al., 
2011). Health status is measured using 5 
dimensions; mobility, self-care, usual 
activities, pain/discomfort, and 
anxiety/depression 
The Short Form 
(36) Health 
Survey (FS-36)  
Dowrick 2000  
Sharif 2012  
Quality of life  
(Health status)  
36- item self-report tool.  
Several versions of the FS-









Self-report tool.  Several versions of 
the IRBAS are available (Cohen et 










Clinician administered assessment (Gold 
2014)  
Legend: *Tools used to measure outcomes outside our interest are not included in the table.   
 
3.2.7 Risk of bias (RoB) assessment of included studies  
The nine included RCTs were assessed for risk of bias in accordance with our protocol. 




graded lack of blinding down for all of the 9 studies, under the category “assessment of 
blinding of participant and personnel” during the RoB assessment.    
Five of the studies (Dalgard (2006), Cohen, O’Leary & Foran, 2010, Günadyɩn & Barlas, 
2017, Kumar & Gupta, 2015 and Sharif & Ashkani & Zoladl, 2012) were considered to have 
unclear risk of bias in the randomization process. Four of these used a sub-optimal method 
and one had poor description of the randomization process. We attempted, without success, to 
contact the author of one of these five studies (Günadyɩn & Barlas, 2017) to get more 
information on the randomization process as the article provides scarce information: 
“Randomization methods were employed to achieve homogeneity among the groups”.    
The result of the risk of bias assessment is displayed in table 10 and generated using the 
RevMan tool (Review Manager, 2014). The complete risk of bias assessment is found in 
appendix 5. 






3.2.8 Summary of findings     
Three meta-analyses and forest plots were created for the outcomes depression and 
psychosocial functioning. One of these was a subgroup analysis looking into family group 
psychoeducation versus patient group psychoeducation. The quality of evidence gained from 
the two main meta-analyses were evaluated by using The Grading of Recommendations 
Assessment (GRADE) online software developed by the GRADE working group to conduct 
systematic, transparent and pragmatic grading of strength of evidence from meta-analyses 
(Guyatt G. H. et al. 2008). The summary of findings from the GRADE evaluation is presented 








Table 11. Summary of findings for the comparisons  
Explanations:  
1) RR: relative risk; CI: Confidens interval, SMD, SD 
2) Certainty of evidence for Depression symptoms at 4-6 is downgraded due to imprecision. 
3) Certainty of evidence for Depression symptoms at 3 months is downgraded due to inconsistency  
4) Certainty of evidence for Depression symptoms at 12 months is downgraded due to imprecision 
5) Certainty of evidence for Relapse is downgraded due to imprecision 
6) Psychosocial functioning at 4-5 weeks is downgraded due to serious imprecision 
7) Psychosocial functioning at 12 weeks is downgraded due to serious imprecision 
Group psychoeducation in conjunction with treatment as usual versus treatment as usual 
Population: Adults with Major Depressive Disorder 
Intervention: Group psychoeducation in conjunction with treatment as usual 
Comparison: treatment as usual  
Outcomes Illustrative comparative 
effect (95% CI)  
Relativ effect 
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3.3 Effect of group psychoeducation and TAU versus TAU 
Reported outcomes for the comparison group PE and TAU versus TAU were depression, 
quality of life, relapse, and psychosocial functioning. Sub-group analysis was made for family 
group psychoeducation versus patient group psychoeducation.   
3.3.1 Effect on depression 
Eight studies measured effect of GPE on depression. BDI was used to evaluate effect of the 
intervention in 7 of the studies and HAM-D was used in two studies. One study (Cohen, 
O’Leary & Foran, 2010) reported both BDI and HAM-D. The HAM-D result was chosen for 
further analysis.  
Chetty & Hoque (2013) did not report standard deviation and the results could therefore not 
be included in the meta-analysis. Seven studies (Aagaard et al., 2017, Casañas et al., 2012, 
Cohen, O’Leary & Foran, 2010, Dalgard, 2006, Dowrick et al., 2000,  Günadyɩn & Barlas, 
2017 and Kumar & Gupta, 2015) were considered to be sufficiently similar and therefore 
included in a meta-analysis, giving a total of 969 pooled patients. Meta-analysis was made for 
follow-up after 4-6 weeks, 3 months, 6 months and 12 months. Only one study, (Aagaard et 
al., 2017), had follow-up of patients beyond 12 months, assessing the patients at 18 months 






Table 12. Results of GPE and TAU versus TAU on MDD  
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Legend: Interv. = intervention group, Control= control group, SD=standard deviation, N= no of 
participants  
* Split results, reporting effect on mild and moderate depression are available, but not included.   







A forest plot displaying the effect of GPE on depression at various follow-up times (subtotals 
at 4-6 weeks, 3 months, 6 months and 12 months) after randomization was made using the 
RevMan tool (Review Manager, 2014) and displayed in figure 4.   
 







The effect of GPE on reduction of depression after 4-6 weeks is (n=204): SMD = -0.32 (CI: -
0.59 to -0.04), with no statistical evidence of heterogeneity (I2=0%, P=0.39), and the result is 
significant at 5% level (P=0.03). None of the three individual studies give a significant result 
as the confidence intervals are crossing the line of no effect, but the pooled result shows a 
significant effect with a small effect size, favouring GPE in conjunction with TAU over TAU 
on reduction of depression.  
The effect of GPE on reduction of depression after 3 months is (n=432): SMD= -0.61 (CI: -
1.14 to -0.09), with statistical evidence of heterogeneity (I2 = 82% and P=0.0007). The effect 
is significant at 5% level (P=0.02), but the high level of heterogeneity indicates systematic 
differences among the studies. Three out of four studies show some reduction in level of 
depression in the group receiving psychoeducation. One study (Günadyɩn & Barlas, 2017) has 
no significant result as the confidence interval is crossing the line of no effect. The two 
studies with highest positive effect of the intervention (Cohen, O’Leary & Foran, 2010 and 
Kumar & Gupta, 2015) involves a caregiver and these studies therefore belong to the FGPE 
sub-group.  
The effect of GPE on depression after 6 months small (n= 756): SMD= -0.21 (CI: -0.38 to -
0.04). The combined effect of the five studies is significant at 5% level (P=0.01), in favour of 
GPE. Three of the studies are crossing the line of no effect (Aagaard et al.,2017, Casañas et 
al., 2012, and Dowrick et al., 2000). There is no statistical evidence of heterogeneity (I2=23%, 
P=0.27). 
Only two studies have measurements from patient assessment after 12 months (Aagaard et al., 




SMD= 0.22 (CI: -0.02 to 0.45) and crossing the line of no effect and hence not significant at 
5% level (P=0.08). There is no statistical evidence of heterogeneity (I2=0%, P=1.00).  
We graded the certainty of the body of evidence for the comparison GPE in conjunction with 
TAU versus TAU to be of moderate quality except for at 6 months where the body of 
evidence is graded high. The GRADE tables are submitted in appendix 8. 
3.3.1.1 Sub-group analysis  
We wanted to examine the effect on the patient when including a family member or a 
caregiver in the psychoeducation program;FGPE. Sub-analysis was made for the effect of 
FGPE and TAU compared to patient group psychoeducation (PGPE) and TAU on depression. 
It was possible to make a sub-group meta-analysis, comparing FGPE and PGPE on the effect 
of depression, at 3 months after randomization. Two studies (Casañas et al., 2012 and 
Günadyɩn & Barlas, 2017) measured the effect of PGPE and two studies (Cohen, O’ Leary & 
Foran, 2010 and Kumar & Gupta, 2015) measured the effect of FGPE on depression. The 
total number of participants in the meta-analysis was 432. The numeric result used in this sub-





Figure 5. Sub-group analysis: FGPE versus PGPE analysis.  
 
 
Effect of FGPE at three months follow up (n= 99) is: SMD= -1.21 (CI: -1.64 to -0.78). There 
is no statistical evidence of heterogeneity (I2=0%, P=0.63) and the effect is significant at <1% 
level (P<0.00001) suggesting a considerable effect of FGPE on reducing level of depression. 
The test for sub-group difference (Chi2 =16.03, P<0.0001) shows that there is a significant 
difference in effect between FGPE and PGPE.      
Effect of PGPE at three months is small (n=333), SMD= -0.22 (CI: -0.44 to -0.01), with no 
statistical evidence of heterogeneity (I2=0% and P=0.39). The effect is significant at 5% level 
(P=0.04). One of the two studies (Günadyɩn & Barlas, 2017) in this sub-group analysis has 
confidence interval crossing the line of no effect. But the combined result of the two studies 




3.3.2 Effect on quality of life 
Three studies measured the effect of PGPE in conjunction with TAU versus TAU on quality 
of life (Casañas et al., 2012, Dowrick et al., 2000 and Sharif & Ashkani & Zoladl, 2012). 
Casañas et al. (2012) used EQ-D5 as measuring tool while the two others used FS-36 to 
measure quality of life. Sharif, Nourian, Ashkani & Zoladl (2012) reported results in a 
controversial manner and these results are excluded from this review as discussed in chapter 
3.2.6. Dowrick et al. (2000) reported the results in subgroups and it is therefore impossible to 
include this study in a meta-analysis on the outcome quality of life. The range of the means 
for the control group was 34.05- 70.38.  The range of the means for the PGPE was 38.87-
68.31. The standard deviation of the various groups seems high in this study. The results form 
Dowrick et al. (2000) are found in table 14 and table 15 respectively.         
Casañas et al. (2012) found no significant effect of PGPE in conjunction with TAU on quality 
of life as compared to TAU. Dowrick et al. (2000) found some effect of PGPE on quality of 
life after 6 months, but no effect after 12 months when compared to treatment as usual. The 
results from Casañas et al. (2012) is presented in table 13.  
 





Mean score (SD) 
6 months 
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9 months 





































































 Legend: SD= standard deviation, CI= confidence interval  
*difference was calculated between follow-up measurement and baseline measurement by the authors. 




Table 14. Results of PGPE and TAU versus TAU on quality of life (Dowrick et al.,2000)  
Treatment v 
control 
 Outcome  6 months  12 months  
Mean 
(95% CI) 





SF-36 (mental role)*  12.70 
(0.46 to 24.94) 
0.042 -4.02 
(-14.53 to 6.49) 
0.454 
SF-36 (social function) ** 8.66 
(0.07 to 17.25) 
0.048 2.36 
(-6.10 to 10.83) 
0.584 
SF-36 (mental health) *** 6.95 
(0,76 to 13,14) 
0.028 -3.25 
(-8.47 to 1.97) 
0.223 
 
Legend: CI= confidence interval, *after controlling for baseline BDI score, mental role scores and random centre 
effect.  **after controlling for baseline BDI score, social functioning scores and random centre effect.  ***after 
controlling for baseline BDI score, mental health scores and random centre effect.  
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3.3.3 Effect on relapse  
One study (Aagaard et al., 2017) reported on admittance to psychiatric hospital 2 years before 
and two years after the date of inclusion. This outcome can be interpreted as a measurement 
for relapse. The results, given in table 16 show no significant difference between intervention 
group and control group on admittance to psychiatric hospital.   
Table 16. Admittance to psychiatric hospital 2 years before and 2 years after date of inclusion 
to the study (Aagaard et al., 2017)   
No of admissions Intervention Controls 

























Total  42 
 
42 38 38 





















3.3.4 Effect on psychosocial functioning 
Cohen, O’Leary and Foran (2010) and Kumar and Gupta (2015) examined the effect of FGPE 
on psychosocial functioning using the measurement tools IRBAS and GAF, respectively. The 
numeric results are displayed in table 17. The pooled effects after 4 to 6 weeks and after 12 
weeks are displayed in a forest plot, figure 6. An increase in the level of psychosocial 





Table 17. Results of FGPE and TAU vs TAU on psychosocial functioning 
Study Year  
No  
Measurement tool  
4-5 weeks  
Mean  
(SD)  






Cohen 2010  



































Legend: GAF= Global assessment of functioning, IRBAS=Illness-Related Behaviors and Attitudes Scale, 
SD=standard deviation  
 
Figure 6. Meta-analysis of FGPE and TAU vs TAU on psychosocial functioning 
 
 
There was a considerable effect of FGPE on psychosocial functioning after 4-5 weeks, 
(n=102): SMD= 1.07 (CI: 0.65 to 1.48). There is no statistical evidence of heterogeneity 
(I2=0%, P=0.49) and the effect is significant at <5% level (P<0.00001).    
There was also an effect of FGPE on psychosocial functioning after 3 months (n=99): SMD= 
0.98 (CI: 0.56 to 1.40). There is no statistical evidence of heterogeneity (I2=0%, P=0.67) and 




This is suggestive of a positive effect of FGPE in conjunction with TAU versus TAU on 
psychosocial functioning after 4-5 weeks and after 3 months. We graded the body of evidence 
for this comparison to be of low quality, see table 17. There is a serious downgrade of the 







4.1 Summary of main results  
This review summarizes research on the effect of GPE for adults with major depressive 
disorder. We preselected six outcomes of interest, including quality of life and outcomes we 
considered of importance for quality of life such as depression severity, level of psychosocial 
functioning, relapse, and treatment adherence. Mortality was also prespecified as an outcome 
of interest. We summarize the main findings below.   
4.2 Effect of GPE and TAU versus TAU 
4.2.1 Effect on depression 
The pooled effects of GPE in conjunction with TAU versus TAU on severity of symptoms of 
depression at 4-6 weeks and at 6 months after randomization showed a small and statistically 
significant effect. At 3 months the result showed substantial heterogeneity and the effect was 
not significant at 12 months post randomization. The high heterogeneity at 3 months cannot 
be random as the p-value shows significant systematic difference between the studies. Hence, 
our confidence in the pooled effect on reducing depression, measured at 3 months, is low. It is 
however interesting to elaborate on the mechanisms accounting for the systematic 
heterogeneity at 3 months. This will be discussed under the sub-group analysis.   
There are five studies contributing to the body of evidence at 6 months post randomization, 
included in the meta-analysis. The pooled effect of the five studies show a small benefit of 
GPE in conjunction with TAU as compared to TAU alone. A cautious conclusion in favor of 




The pooled effect of GPE in conjunction with TAU on depression after 12 months did not 
reach the statistical significance. GPE in conjunction with TAU does not seem to have the 
desired effect on reducing depression at 12 months after randomization when compared to 
TAU.   
The evidence of the effect of GPE in conjunction with TAU compared to TAU was evaluated 
by applying GRADE methodology. The GRADE evidence was considered to be of moderate 
confidence at 4-6 weeks, at 3 months and at 12 months but of high confidence at 6 months. At 
4-6 weeks assessment, the quality of evidence was graded down from high to moderate due to 
serious imprecision; too small sample size. At 3 months assessment, the quality of evidence 
was downgraded due to serious inconsistency. At 12 months assessment, the small sample 
size led to downgrading. 
When looking at SMD from the various follow-up times compared to the scales of BDI and 
HAM-D, the size of the change in level of depression seems to be small. Below is an account 
for the clinical grading of the participants according to the BDI or HAM-D score measured.    
Table 17. Level of depression as expressed by the clinical grading tools, BDI, BDI-II and 
HAM-D. 















































For a researcher it is encouraging to get a significantly lower result in an intervention group, 
however a small effect of treatment does not necessarily reduce the participants experienced 




the most important outcome. Some of the 9 included studies have also measured other 
outcomes and concurrent improvement of several outcomes gives a stronger evidence of 
effect. BDI and HAM-D are self-assessment tools for depression symptoms. This means that 
the participants in the intervention group may have overrated their self-assessment score. 
Resulting in an artificially inflated effect of the intervention. We consider the evidence of the 
positive effect of GPE on depression to be valid, although it is of low magnitude.       
4.2.1.1 Sub-group analysis 
At three months follow-up the results on depression showed significant hetrogeniety. We elaborated 
on this by performing a sub-group analysis. The four studies in the 3-month analysis are clustered into 
two groups. The most encouraging effect is found in the studies performed by Cohen, O’Leary and 
Foran (2010) and Kumar & Gupta (2015). These two studies showed significant and similar large 
positive effect of FGPE on depression. Casañas et al. (2012) and Günadyɩn & Barlas (2017) showed a 
much smaller and non-significant effect of PGPE. These 4 studies are conducted in different countries 
(India, Spain and Turkey and USA), in different socioeconomic conditions and different cultures. The 
two studies contributing to the more effective cluster, have included a caregiver in the intervention and 
hence measures the effect of FGPE. The two studies showing greatest effect are Cohen, O’Leary & 
Foran (2010) studying FGPE amongst depressed females including their spouse as caregiver in Long 
Island, New York, USA and Kumar & Gupta (2015) studying depressed adults in New Delhi, India. In 
the Kumar & Gupta (2015) study, the majority of the depressed participants and their caregivers were 
males. In sum, FGPE in conjunction with TAU shows encouraging positive results on reducing 
depressive symptoms, in studies from two vastly different contexts. It should however be noted that 
the sample size is small (n=48).   
In conclusion, although there are few studies, when assessed at 3 months after randomization, FGPE 




At 6 months after randomization, there are no data recorded for FGPE as both studies examining effect 
of FGPE stops at 3 months follow-up. Beyond this point we have no information on the effect of 
FGPE. 
It should be noted that the studies measuring FGPE have follow-up assessment between 4 weeks and 3 
months, whereas the studies assessing PGPE have follow-up assessment at from 5 weeks to 12 
months. Hence this review provides no information on the effect of FGPE after 3 months and very 
little information on PGPE before 6 months.  
The bulk of results on PGPE is reported at 6 months assessment. Aagaard et al. (2017) is the only 
study having outcome measures (hospital admittance) at 2 years after randomization. Posternak et al. 
(2006) studied the course of unipolar MDD in patients not receiving somatic treatment and found that 
there is a median time to recovery of 23 weeks (5-6 months). Furthermore, the results from the study 
suggests that a high rate of recovery occurs within the first 3-4 months of an episode. The positive 
effect on depression and psychosocial functioning could perhaps be explained by time as a 
confounder. PGPE and other intervention may show similar positive effect in this early period, but we 
lack data to make any conclusions on the effect of PGPE within the first 3 months.   
4.2.2 Effect on quality of life 
Only three studies reported on quality of life; (Casañas et al., 2012, Dowrick et al., 2000 and Sharif, 
Nourian, Ashkani & Zoladl, 2012). The results from Sharif, Nourian, Ashkani & Zoladl (2012) will 
not be discussed, for reasons outlined in chapter 3.3.2.  
Dowrick et al. (2000) show some effects on improving quality of life at 6 months, but the positive 
effect of psychoeducation on quality of life had diminished by 12 months. Casañas et al. (2012) did 
not find any significant effect on quality of life of GPE in conjunction to TAU versus TAU at 3 
months, 6months and 9 months. This corresponds well with the small or even absent effect on 




4.2.3 Effect on relapse   
One study (Aagaard et al., 2017) measured relapse, reporting this outcome as admittance to psychiatric 
hospital. The study found no significant difference between intervention group and control group on 
admittance to psychiatric hospital 2 years before and 2 years after intervention. This corresponds well 
with the lack of effect on depression in this study, se chapter 3.3.3.  
4.2.4 Effect on psychosocial functioning 
The two studies examining the effect of GPE on psychosocial functioning were both investigating the 
effect of FGPE (Cohen, O’Leary & Foran, 2010 and Kumar & Gupta, 2015). The SMD effect of 
FGPE in conjunction with TAU on psychosocial functioning were positive and significant both at 4-5 
weeks and at 3 months, suggesting a positive effect of FGPE in conjunction with TAU when 
compared to TAU alone. The positive effects were reported as an increased level of psychosocial 
functioning. Although the number of participants contributing to the evidence is small, (n=46 at 4-5 
weeks and n= 48 at 3 months) the analysis indicates that it is beneficial for the patient to involve their 
caregiver in psychoeducational treatment. However, we do not have any measurements on 
psychosocial functioning beyond 3 months. The evidence was evaluated using the GRADE approach, 
to be of moderate confidence due to small number of participants (imprecision). These results suggest 
that caretakers may play an important a role on improving psychosocial functioning in patients with 
major depressive disorder.        
4.3 Agreement with other reviews   
We have compared our results with other systematic reviews. We found three relevant 
systematic reviews that have been conducted recently. The three are discussed below. 
Effectiveness of psychoeducation for depression: A systematic review 
Tursi et al. (2013) conducted a systematic review on the effectiveness of psychoeducation for 
depression. In this systematic review there were seven studies applying PE for patients in a 




studies included families in the intervention. Two studies overlapped with our overview 
(Dalgard, 2006 and Dowrick et al., 2000). The results reported are suggesting an association 
between increased knowledge about depression and its treatment and better prognosis in 
depression. The main conclusion is that there are only a few studies conducted regarding 
effectiveness on adult patients with MDD. The authors suggest, despite few publications, that 
psychoeducation is effective in improving the clinical course, treatment adherence, and 
psychosocial functioning of depressed patients (Tursi et al., 2013). Tursi et al. (2013) 
conclude that further RCTs on PE for patients with MDD are still needed to better elucidate 
the effectiveness of PE. 
Psychoeducational treatment and prevention of depression: The “coping with depression” 
course thirty years later. This meta-analysis conducted by Cuijpers, Munoz, Clarke & 
Lewinsohn (2009) looked at the Coping with Depression (CWD) course as psychoeducational 
intervention for prevention and treatment of depression. 18 studies were examining treatment 
of depression. One study was overlapping with our review (Dowrick et al., 2000). The studies 
differed considerably from each other, ranging from internet interventions without any 
professional support to minority groups, adolescents to older adults. Results showed an 
overall mean effect size in reduction of depression symptoms of 0.28 (95% CI: 0.18 to 0.38), 
with low to moderate heterogeneity (I2=31.87). They compared the CWD with other 
psychotherapies (7 studies) and the mean effect size was a non-significant difference in favor 
of the other psychotherapies – 0.05 (95% CI: -0.25 to -0.16), with moderate heterogeneity 
(I2=48.71). Cuijpers, Munoz, Clarke & Lewinsohn (2009) conclude that the effect sizes found 
were relatively small and that although many studies found clear evidence of efficacy other 
studies did not find any effect. They argue that more research is needed to examine the 




their study is that very few studies have compared the efficacy of CWD to antidepressants and 
other psychological treatments, and that more research is needed. They also mention that 
there is unclarity in terms of which elements in the CWD modules that are effective. 
“Family matters”: A systematic review of the evidence for family psychoeducation for major 
depressive disorder  
This systematic review conducted by Brandy, Kangas & McGill (2016) is reviewing the 
evidence for family psychoeducation for MDD. This article is reviewing multi-family 
psychoeducation (MFPE) versus single family intervention (FPE) for MDD, peer-led FPE 
versus clinical led groups for MDD and FPE for mixed diagnosis versus FPE for MDD only. 
Nine data samples were included in this review and one study was overlapping with our 
review (Kumar & Gupta, 2015). Two FPE studies, with groups consisting of patients and 
caregiver and not only caregivers, other than Kumar & Gupta (2015) reported positive 
outcomes for the patients, one of them for depressed adolescents. None of the MFPE 
interventions included the patients. The findings of this review indicate tentative support for 
FPE for MDD in improving patient functioning and family well-being, based on a small 
number of international studies. 
Altogether it seems the results in the previous comparable systematic reviews are in 
accordance with our findings for group psychoeducation; there are few RCT studies 
conducted on GPE for depression available, and the effect sizes found on reducing depression 
symptoms and psychosocial functioning are small. Although the studies are few, our review 
contributes with a new dimension in finding a substantial statistically significant difference in 




4.4 Certainty of the evidence     
The nature of the invention does not allow blinding of personnel and participant. This was 
taken into consideration in the GRADE assessment. In several of the studies the participants 
are self-reporting the experienced level of depression, because there is no available objective 
measure. This lack of blinding may result in an over estimation of the positive effect of the 
intervention, (Hawthorne effect). 
We graded the confidence in the body of evidence for our comparison in regard to all 
outcomes of interest. We downgraded the confidence primarily for heterogeneity and for 
small number of events.To sum up, our confidence in the certainty of the evidence varies 
from low to high. This means that the results where the body of evidence is graded low has to 
be interpreted with caution. 
4.5 Transferability     
The nine included studies have been conducted in vastly different socioeconomic and cultural 
settings. High-, middle-, and low-income countries are all represented amongst our material 
and four continents are represented. The two studies on family psychoeducation show similar, 
encouraging results despite the huge difference in socioeconomic and cultural setting under 
which these studies were conducted. Group psychoeducation, and in particular family group 
psychoeducation, is a type of intervention that always carries a cultural aspect and it may well 
be the case that the treatment is not accepted or effective in all cultures or for all groups of 
patients. It is a strength for the interpretation of the result that two very different studies give 
similar and positive results for the patient, with consistent positive effect on both level of 
depression and on psychosocial functioning. However, generalization of these results cannot 
be easily done due to imprecision caused by few participants. Additional evidence is needed 




4.6 Ethics     
All the included studies are conducted in an ethically acceptable manner. There is no placebo 
treatment in the studies, meaning there will be no ethical dilemmas regarding the 
administration of a placebo intervention to ill patients. Six of the studies have reported that 
they used written informed consent for all the participants and five studies report that the 
study has acceptance from an ethical committee. All participants seem to have had access to 
both healthcare professionals and pharmacological treatment.  
The ethics of providing GPE as a treatment option is solely dependent on its proven 
effectiveness because the intervention has no known negative side-effects.  
4.7 Strengths and weaknesses     
A strength of this review is that all studies included have RCT design, although four of them 
were somehow unclear about the randomization process. We had enough comparable 
evidence to conduct three meta-analyses. The review protocol was preregistered in 
PROSPERO, minor changes in the protocol are described in chapter 2.8. 
There are no suicides reported amongst any of the included patients in our studies. Suicide is 
the ultimate tragical outcome of MDD and research into suicide prevention is of great 
importance. Our protocol described suicide as an outcome of interest, but in hindsight we 
experienced that this study design does not give the desired knowledge regarding suicide 
because the event is too rare.    
There were only two studies on FGPE. It would have been desirable to have a few more 
studies to underpin or reject our findings. More knowledge on the effect of the intervention is 




groups. FGPE show improvement in two of the outcomes (depression and psychosocial 
functioning). This strengthens the trust in the effectiveness of the intervention.  
It is possible that we did not find all relevant studies during the search and screening process, 
but we consider this to be a minor chance and a minor limitation to this review. It might also 
be studies that are published after we ended our data search. 
Other limitations to our review are that we did not make any restrictions on measurements 
tools in our inclusion criteria, nor in the manner in which the outcome data were gathered. 
Neither did we decide on clinical cut-off points for the outcomes, but rather looked at the 
change of overall baseline levels of depression and psychosocial functioning.  
Last but not least, it would have been a strength to the systematic review if we have had a 
professional background in clinical mental health, previous to performing this review. 
However, we consulted several clinicians and the project leader for drug free treatment for 
psychiatric illness at Vestre Viken health authority and believe this is a minor limitation to 
this review.   
4.8  Implication for practice/policy     
Bearing in mind the universal shortage of healthcare resources and vulnerability of patients 
with MDD, PGPE in conjunction with TAU is according to this review not a satisfactory 
treatment option for patients with MDD. There is however a small effect of GPE on 
depression at 4-6 weeks, 3 months and 6 months. This indicates that the intervention has 
benefit to the patients. We have found no evidence supporting any change in admissions to 





FGPE in conjunction with TAU needs a greater body of evidence to earn a universal 
recommendation for patients with MDD. If further research confirms a desired effect of 
FGPE, any potential practical barriers must be removed for successful implementation of 
FGPE. Knowledge into why some patients drop out and why some patients does not have 
desired effect is of importance. There is uncertainty regarding whether the patient and their 
caregiver will opt for attending FGPE in all contexts. It might be challenging for caregivers to 
commit to attending the whole FGPE program and some cultures may not accept FGPE or 
achieve desired effect of FGPE. Timing the group sessions may prove difficult, because the 
participants might need to start treatment at different times. FGPE may not be a desirable 
treatment for all as some patients may not want to involve their family in their suffering, and 
some may see the family as part of their problem and would rather seek a therapist on their 
own. Further investigation on practical barriers and solutions to optimal utilization of FPE 
programs is recommended. 
4.9  Implication for further research   
There is a worldwide demand for effective, acceptable and available treatments for 
depression. FGPE has potential to be of great benefit for depressed patients and solid 
documentation is necessary before one can recommend the intervention on a large scale.  
The substantial knowledge into the shared heritability of common mental disorders, published 
in Science in June 2018 (The Brainstorm Consortium, Antitila et al., 2018), supports the need 
for further investigation into family interventions. It also supports the demand for more 
knowledge on the effect of inviting a loved one (caregiver) into the treatment alliance.      
Further research is needed to close the current knowledge gaps, below are some questions that 




• What is the long-term effect of FGPE on MDD? 
• Is FGPE beneficial for families who suffer from a familial predisposition to mental 
health disorders and can these be treated in multi-family groups? 
• What are the practical obstacles to implementation of GPE and how can they be 
overcome?   
• What effect does GPE/FGPE have in different societies and for different groups of 
patients? 
• Can FGPE play a role in prevention of MDD and help prevent relapse?  
Further knowledge into drug-free alternatives in the treatment of patients with MDD is of 
great importance in the Norwegian context as all regional health authorities are instructed by 
the minister of health to provide drug-free treatment option for psychiatric diseases (Brev fra 
Helse- og omsorgsdepartementet til de regionale helseforetakene, 2015). Treatment offered to 
the patient must be effective, well tolerated, safe and well documented. FGPE in conjunction 
with TAU show encouraging results. Research to establish more solid evidence for, or 
against, this intervention should be performed, preferably in a collaborative manner, including 
all Norwegian regional health authorities. Use of the intervention prior to further knowledge 
must be done with caution.   
4.10 Conclusion  
The effect of GPE in conjunction with treatment as usual without involving caregiver does 
not seem to have substantial benefits, when compared to treatment as usual and it is therefore 
unjustifiable to recommend this intervention on a large scale. Further investigation into GPE 
may provide new evidence.   
FGPE involving participants (patients) and their caregiver seem to have beneficial effects on 




usual. The evidence is based on a very small number of participants and the results for FGPE 
carry great uncertainties. If further knowledge on FGPE supports effectiveness suggested in 
this review, this intervention could be an important contributor to treatment of depression 
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6.1 Appendix 1: Protocol published in PROSPERO 
 
PROSPERO 
International prospective register of systematic reviews 
 Print |  PDF 
Effect of group psychoeducation for major depressive disorder compared with 
pharmacological and/or other psychological treatment: a systematic review 
Helene Sandberg, Åshild Roaldset 
Citation 
Helene Sandberg, Åshild Roaldset. Effect of group psychoeducation for major depressive 
disorder compared with pharmacological and/or other psychological treatment: a systematic 
review. PROSPERO 2017 CRD42017077110 Available 
from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42017077110 
Review question 
Is group psychoeducation effective in improving quality of life in adults with major depressive 
disorder compared to pharmacological treatment and/or other psychological treatment? 
Searches 
The following databases will be searched: MEDLINE, EMBASE, The Cochrane Library (Central), 
PsycINFO, PubMed, CINAHL. Other databases will be considered in discussion with a search 
librarian. The reference lists of systematic reviews, literature reviews, and other relevant publications 
will also be checked manually to identify any relevant studies not covered by the database searches. 
Databases will be searched from the year 2000, because consensus about the critical elements of 
family psychoeducation was developed in 1999 (Substance Abuse and Mental Health Services 
Administration 2009). 
Types of study to be included 
Types of study to be included: randomized controlled trials (RCTs) and non-randomized controlled 
trials (non-RCTs), controlled before-and-after studies (CBAs), interrupted time series (ITS), 
prospective and retrospective cohort studies with a control group are eligible for inclusion. In the 
event that several high-quality RCTs and non-RCTs are included, we will consider not including other 
study designs. Cluster RCTs analysed on an individual level must be adjusted for intra cluster 
correlation (ICC). 




Major depressive disorder (MDD – clinical depression), ICD10, F32.2, F32.3, F33.2, F33.3, F34.0, 
F34.1 (ICD10, WHO, 2013) is a common mental disorder that occurs in all ages worldwide. MDD is 
an episodic disorder with a chronic or long-term outcome and increased risk of death. There are more 
than 300 million people of all ages with depressive disorder globally (WHO 2017). According to 
WHO (WHO 2017) depression is a leading cause of disease burden and accounted for 4.3% of the 
global burden of disease in 2010 (Ferrari, 2013). Depression is one of the largest single causes of 
disability worldwide. MDD and Dysthymia accounted for 2.5% of global disability- adjusted life years 
(DALYS), a measure of reduced health year, and it is also associated with lower work productivity, 
suicide and ischemic heart disease (Ferrari, 2013). According to WHO, persons with MDD and 
schizophrenia have a 40-60% greater chance of dying prematurely compared to the general 
population. Close to 800,000 people die of suicide every year due to all causes (WHO 2017). 
Reduction in healthy life years and the associated health issues due to depression has not only an 
impact on the affected persons and their families but also the economy worldwide. 
There are many non-medical interventions for depression disorder. Cochrane Common Mental 
Disorder lists 87 different psychological therapies (Cochrane CCDAN n.d.). According to the National 
Institute of Mental Health, common antidepressant medications (National institute of mental health, 
Mental Health Medication) are; Selective Serotonin Reuptake Inhibitor (SSRIs), serotonin and 
norepinephrine reuptake inhibitors (SNRIs), Bupropion, Tricyclic Antidepressants (TCAs), 
Tetracyclics Antidepressant, and monoamine oxidase inhibitors (MAOIs). 
Psychoeducation is a didactic program aiming to give the participants sound knowledge of the 
condition and learn how to accept it and cope with it successfully. The intervention can be used for 
many different conditions and will often involve caregivers such as family and friends. The 
intervention is an independent therapy and is often based on cognitive behavior principles. The 
psychoeducation program can include practical tasks, making the participants practice skills such as 
self-assertiveness, communication and problem solving. The participants are empowered through the 
program and they are not considered to be patients in the psychoeducation setting (Motlova 2017). 
The effect of medication and psychological therapies for depression are continuously studied and 
disputed (Nasjonalt kunnskapssenter for helsetjenesten, 2009, p 16). Psychoeducation has proven to be 
beneficial to patients suffering from psychosis and bipolar affective disorder, but there is currently a 
knowledge gap regarding psychoeducation and major depressive disorder (McFarlane 2016). 
Participants/population 
Patients with MDD, older than 18 years. For inclusion purposes, we will look at study descriptions of 
participants rather than clinical codes (ICD10). We will exclude studies with more than 50% of 
patients with medical comorbidities (e.g. cancer, diabetes). Furthermore, we will exclude studies with 
more than 50% of patients with perinatal depression, bipolar affective disorder and mental 
impairment, including dementia. 
Intervention(s), exposure(s) 
" Psychoeducation could be defined as a patient’s empowering training targeted at promoting 
awareness and proactivity, providing tools to manage, cope and live with a chronic condition (i.e. 




communication), and changing behaviors and attitudes related to the condition. Psychoeducation 
replaces guilt by responsibility, helplessness by proactive care and denial by awareness." (Colom 
2011). 
We will include group psychoeducation that has the following characteristics (McFarlane 2016): 
•is provided to groups of patients or groups consisting of one or more patient with their care givers 
(family members, friends or other) 
•is provided by a health care professional 
•includes exercises in practical skills relevant for the patient and family group such as coping 
strategies, behavior, communication, social interactions and problem solving 
•aims at giving knowledge on depression and treatment of depression 
•is specific for patients with depression 
We will include all durations (doses) of group psychoeducation as long as it is minimum one 60 
minute session per week. 
Comparator(s)/control 
We will include the following comparisons: 
1.Group psychoeducation compared with antidepressant medications. We will accept the 
antidepressant medications listed above. 
2.Group psychoeducation plus antidepressant medications (as listed above) compared with 
antidepressant medications only. 
3.Group psychoeducation compared with other psychological intervention (psychological 
interventions in the Cochrane CCDAN lists of 87 interventions will be included). 
4.Group psychoeducation plus other psychological intervention compared to other psychological 
intervention (as listed above). 
5.Group psychoeducation plus antidepressant medications compared to other psychological 




Patients’ quality of life, mortality (suicide), depression severity. 
Secondary outcome(s) 
Level of psychosocial functioning, relapses, treatment adherence. 




The search result will be screened using Rayyan software (Mourad et al 2016) by two independent 
reviewers. Each reviewer will screen the abstracts for PICO; followed by full text reading when 
necessary. Any differences between the two reviewer’s evaluation of articles for inclusion, will be 
discussed and the publication will be inspected, until consensus is achieved. 
The following core data will be extracted from all included studies: 
• Title, authors and other publication details 
• Study design and aim 
• Setting (place and time of recruitment/data collection) 
• Sample characteristics (age, gender, etc.) 
• Intervention characteristics (duration/dose, provider, content, etc)? 
• Methods of outcome measurement (instruments/ tools) 
• Results related to the outcomes 
Risk of bias (quality) assessment 
Two reviewers will first independently and then together assess the risk of bias. For the RCTs 
included we will assess the risk of bias according to the criteria in the Cochrane Handbook for 
Systematic Reviews of Interventions (Higgins and Green 2011). The following processes will be 
studied to assess risk of bias: sequence generation; allocation concealment; blinding of participants 
and personnel; blinding of outcome assessment; incomplete outcome data; selective outcome 
reporting; and other sources of bias. The quality of evidence for all processes will be reported as ‘Low 
Risk’, ‘Unclear Risk’, or ‘High Risk’. When there is no cause for concern the procedure will be 
considered to have low risk of bias. When there may be a risk of bias, but there is either insufficient 
information to assess whether an important risk of bias exists or there is insufficient rationale or 
evidence that an identified problem will introduce bias, we will assign unclear risk of bias. Procedures 
with cause for concern will be assigned high risk of bias. 
For other study-designs than RCTs included, we will use Cochrane EPOC (Effective Practice and 
Organization of Care Group) checklist. The same assessment procedure as for RCTS will be used. In 
the event of disagreement between the two reviewers, the supervisor and co-supervisor will be 
involved to find a solution. 
Strategy for data synthesis 
We will conduct meta-analyses when possible. Data will be summarized and presented narratively in 
text and tables for each comparison. For continuous data, mean difference or standardized mean 
difference and 95% confidence intervals (95% CI) will be used to calculate effect sizes by using the 
Revman 2014 software. We will analyse dichotomous data as risk ratios and 95% confidence intervals 
(95% CI). Revman will be used to pool data (meta-analysis) when we have two or more studies 
reporting the same PICO (Population, Intervention, Comparison, Outcome), and to generate forest 




unclear therapeutic approach making comparisons difficult. For the primary outcomes we will assess 
the certainty of the evidence by using GRADE. Heterogeneity will be considered. We define 
heterogeneity to be when there is great variation in results, non-overlapping CIs, P<0,01 and I > 50% 
(Higgins and Green 2011). We will examine causes for and attempt to explain heterogeneity. 
Analysis of subgroups or subsets 
1. Effect of group composition; group consisting of patients only or patients together with their family 
members or other caregiver 
2. Dose effect of the psychoeducation therapy; 12 sessions (of 1-2 hours duration every week) or less 
will be considered low dose, 13-52 sessions (of 1-2 hours duration every week) will be considered 
moderate duration, and 52 sessions and above (1-2 hours duration every week) will be considered high 
dose (Xia et al 2011). 
Contact details for further information 
Helene Sandberg 
sandberg.helene@gmail.com 
Organisational affiliation of the review 
The Arctic University of Norway (UiT) uit.no 
Review team members and their organisational affiliations 
Ms Helene Sandberg. UiT 
Ms Åshild Roaldset. UiT 
Collaborators 
Lien Nguyen. Norwegian Institute of Public Health 
Anticipated or actual start date 
01 September 2017 
Anticipated completion date 
15 May 2018 
Funding sources/sponsors 
None 











Subject index terms status 
Subject indexing assigned by CRD 
Subject index terms 
Bipolar Disorder; Depressive Disorder, Major; Humans; Psychotherapy 
Date of registration in PROSPERO 
30 October 2017 
Date of publication of this version 
15 September 2017 
Details of any existing review of the same topic by the same authors 
 
Stage of review at time of this submission 
Stage Started Completed 
Preliminary searches Yes No 
Piloting of the study selection process No No 
Formal screening of search results against eligibility criteria No No 
Data extraction No No 
Risk of bias (quality) assessment No No 
Data analysis No No 
Versions 
15 September 2017 
PROSPERO 
This information has been provided by the named contact for this review. CRD has accepted 
this information in good faith and registered the review in PROSPERO. CRD bears no 











6.2 Appendix 2: Search strategy in electronic databases       
 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed 
Citations, Ovid  
MEDLINE(R) Daily and Ovid MEDLINE(R) 1946 to Present 
Date for search: 19.09.2017 
# Searches Results 
1 Mood disorders/ 13360 
2 Depressive disorder, major/ 26064 
 
3 Depressive disorder/ 69663 
4 Dysthymic disorder/ 1135 
5 Depression/ 101227 
6 Cyclothymic Disorder/ 636 




8 or/1-7  469371 
 
9 (psychoeducat* or psycho-educat*).mp. 5307 
 
10 ((famil* or group?) adj2 intervention*).ti. 1982 
 
11 8 and (9 or 10) 1780 
 
12 Randomized Controlled Trial/ 481824 
 
13 Non-randomized controlled trials as topic/ 231 
14 Controlled Clinical Trial/ 96877 
15 Controlled Before-After Studies/ 284 
16 Multicenter Study/ 239806 
17 Pragmatic Clinical Trial/  674 
18 Interrupted Time Series Analysis/ 333 
19 (random* or trial or intervention? or effect? or impact? or multicenter 
or multi center or multicentre or multi centre or controlled or control 
group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) 
and (posttest or post test)) or quasiexperiment* or quasi experiment* 
or evaluat* or time series or time point? or repeated measur*).ti,ab. 
8887916 
20 Meta-Analysis/  86965 
21 Meta-Analysis as Topic/ 16461 
22 (((systematic* or literature) adj3 (overview or review* or search*)) or 
meta-anal* or metaanal* or meta-regression* or umbrella review* or 
overview of reviews or review of reviews or (evidence* adj2 synth*) 
or synthesis review*).ti,ab. 
453526 
 
23 Review.pt. and (pubmed or medline).ti,ab. 103522 
 




25 11 and 24 1631 
26 limit 25 to yr="2000-current" 1505 
27 exp Animals/ 21982274 
28 Humans/ 17397204 
29 27 not (27 and 28) 4585070 
30 (news or editorial or comment).pt. 1197945 
31 26 not (29 or 30) 1498 






PsycINFO 1806 to September Week 2 2017  
Date for search: 19.09.2017 
# Searches Results 
1 affective disorders/ 13026 
2 major depression/ 107206 
 








5 recurrent depression/ 735 
 




7 dysthymic disorder/ 1450 
 












11 or/1-10 286205 
12 (psychoeducat* or psycho-educat*).mp. 11217 
13 ((famil* or group?) adj2 intervention*).ti.  2785 
14 11 and (12 or 13) 2153 
15 ("0400" or "0451" or "1800" or "2100").md. [empirical study/ 
prospective study/ quantitative study/ treatment outcome/] 
2197689 
 
16 Experimental Design/ 10593 
17 Between Groups Design/ 108 
18 Quantitative Methods/ 2966 
19 Quasi Experimental Methods/ 143 
20 Experiment Controls/ 888 
21 Pretesting/ 236 
22 Posttesting/ 135 
23 Time Series/ 1830 
24 Repeated Measures/ 644 
25 (random* or trial or intervention? or effect* or impact? or multicenter 
or multi center or multicentre or multi centre or controlled or control 
group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) 
and (posttest or post test)) or quasiexperiment* or quasi experiment* 
or evaluat* or time series or time point? or repeated measur*).ti,ab. 
1913833 
 
26 Meta Analysis/  4048 
27 Systematic Review.md. 17378 
28 (((systematic* or literature) adj3 (overview or review* or search*)) or 
meta-anal* or metaanal* or meta-regression* or umbrella review* or 
overview of reviews or review of reviews or (evidence* adj2 synth*) 
or synthesis review*).ti,ab.  
107679 
 
29 (review and (pubmed or medline)).ti,ab. 12823 




31 14 and 30 2024 
 
32 limit 31 to yr="2000-current" 1719 







Embase 1974 to 2017 September 18  
Date for search: 19.09.2017 
# Searches Results 
1 *mood disorder/ 7662 
2 *depression/ 131918 
3 *Major affective disorder/ 90 
4 *Schizo affective psychosis/ 2238 
5 *Dysthymia/ 2225 
6 *Endogenous depression/ 776 
7 *Involutional depression/ 147 
8 *Treatment resistant depression/ 962 
9 *cyclothymia/ 160 
10 *Major depression/ 23666 
11 (depress* or dysthym* or ((affective or mood) adj disorder*) or 
cyclothym*).ti,ab,kw 
544762 
12 or/1-11 568581 
13 (psychoeducat* or psycho-educat*).mp. 10750 
14 ((famil* or group?) adj2 intervention*).ti. 2393 
15 12 and (13 or 14) 3254 
16 Randomized Controlled Trial/ 472907 
17 Controlled Clinical Trial/ 449115 
18 Quasi Experimental Study/ 4037 
19 Pretest Posttest Control Group Design/  320 
20 Time Series Analysis/ 20124 
21 Experimental Design/ 14803 
22 Multicenter Study/ 165718 
23 Pretest Posttest Design/  2143 
24 (random* or trial or intervention? or effect* or impact? or multicenter 
or multi center or multicentre or multi centre or controlled or control 
group? or (before adj5 after) or (pre adj5 post) or ((pretest or pre test) 
and (posttest or post test)) or quasiexperiment* or quasi experiment* 
or evaluat* or time series or time point? or repeated measur*).ti,ab. 
11743356 
 
25 Meta Analysis/  133938 
26 Systematic Review/ 149802 
27 (((systematic* or literature) adj3 (overview or review* or search*)) or 
meta-anal* or metaanal* or meta-regression* or umbrella review* or 
overview of reviews or review of reviews or (evidence* adj2 synth*) 
or synthesis review*).ti,ab. 
535563 
 
28 (review and (pubmed or medline)).ti,ab. 123202 




30 15 and 29 2863 
31 limit 30 to yr="2000-current"  2696 
32 exp animals/ or exp invertebrate/ or animal experiment/ or animal 
model/ or animal tissue/ or animal cell/ or nonhuman/ 
25250688 
 
33 human/ or normal human/ or human cell/ 19014640 
34 32 not (32 and 33) 6283014 
35 (news or editorial or comment).pt. 547024 
36 31 not (34 or 35) 2692 
37 limit 36 to embase 1757 
 
38 remove duplicates from 37 1658 
 
Cochrane Library (CDSR, DARE, CENTRAL, HTA) 
Date for search: 19.09.2017 
ID Search Hits  
#1 [mh ^"Mood disorders"] 564 
#2 [mh ^"Depressive disorder, major"] 3229 
#3 [mh ^"Depressive disorder"]   5216 
#4 [mh ^"Dysthymic disorder"] 156 
#5 [mh ^Depression] 7307 
#6 [mh ^"Cyclothymic Disorder"] 14 
#7 (depress* or dysthym* or ((affective or mood) next disorder*) or 
cyclothym*):ti,ab,kw   
55136 
 
#8 {or #1-#7}   55136 
 
#9 (psychoeducat* or psycho-educat*):ti,ab,kw   
 
2136 
#10 ((famil* or group or groups) near/2 intervention*) .ti. 3678 
#11 #8 and (#9 or #10) Publication Year from 2000 to 2017, in Cochrane 














#14 (psychoeducat* or psycho-educat*)  2615 
#15 ((famil* or group or groups) near/2 intervention*) .ti 3678 
#16 #13 and (#14 or #15) Publication Year from 2000 to 2017, in 
Cochrane Reviews (Protocols only), Other Reviews and 














Date for search: 19.09.2017 
# Query Limiters/Expanders Last run via Results 
S17 S11 AND S16 Limiters - Exclude MEDLINE records; 
Published Date: 20000101-20170931 
215 
S16 S12 OR S13 OR S14 OR S15  1,007,977 
S15 TI ( ((systematic* or literature) N2 (overview or review* or 
search*)) or meta-anal* or metaanal* or meta-regression* or 
umbrella-review* or "overview of reviews" or "review of 
reviews" or (evidence* N1 synth*) or synthesis-review*) ) OR 
AB ( ((systematic* or literature) N2 (overview or review* or 
search*)) or meta-anal* or metaanal* or meta-regression* or 
umbrella-review* or "overview of reviews" or "review of 
reviews" or (evidence* N1 synth*) or synthesis-review*)  
90,561 
 
S14 TI ( (random* or trial or intervention# or effect* or impact# or 
multicenter or multi-center or multicentre or multi-centre or 
controlled or control group# or (before N4 after) or (pre N4 post) 
or ((pretest or pre-test) and (posttest or post-test)) or 
quasiexperiment* or quasi-experiment* or evaluat* or time-
series or time point# or repeated-measur*) OR AB ( (random* or 
trial or intervention# or effect* or impact# or multicenter or 
multi-center or multicentre or multi-centre or controlled or 
control group# or (before N4 after) or (pre N4 post) or ((pretest 
or pre-test) and (posttest or post-test)) or quasiexperiment* or 
quasi-experiment* or evaluat* or time-series or time point# or 
repeated-measur*) )   
19,921 
 
S13 TI ( (random* or trial or intervention# or effect* or impact# or 
multicenter or multi-center or multicentre or multi-centre 
or controlled or control group# or (before N4 after) or 
(pre N4 post) or ((pretest or pre-test) and (posttest or 
post-test)) or quasiexperiment* or quasi-experiment* or 
evaluat* or time-series or time point# or repeated-
measur*) OR AB ( (random* or trial or intervention# or 
effect* or impact# or multicenter or multi-center or 
multicentre or multi-centre or controlled or control 
group# or (before N4 after) or (pre N4 post) or ((pretest 






quasiexperiment* or quasi-experiment* or evaluat* or 
time-series or time point# or repeated-measur*) )   
 
S12 (DE "Randomized Controlled Trials" OR DE "Pretests Posttests"  
OR DE "Control Groups" OR DE "Evaluation Research" OR DE  
"Quasiexperimental Design" OR DE "Program Validation" OR  
DE "Program Effectiveness" OR DE "Program Evaluation" OR  
DE "Outcomes of Treatment") 
86,174 
S11 S7 AND S10 775 775 
 
S10 S8 OR S9 3,928 
S9 TI ((famil* or group or groups) N1 intervention*) 1,094 
S8S7 TI ( (psychoeducat* or psycho-educat*) ) OR AB ( 
(psychoeducat* or psycho-educat*) ) OR SU ( 
(psychoeducat* or psycho-educat*) )  
2,948 
 
S7 S1 OR S2 OR S3 OR S4 OR S5 OR S6  91,034 
 
S6 TI ( (depress* or dysthym* or ((affective or mood) W0 
disorder*) or mental* ill* or cyclothym*) ) OR AB ( 
(depress* or dysthym* or ((affective or mood) W0 
disorder*) or mental* ill* or cyclothym*) ) OR SU ( 
(depress* or dysthym* or ((affective or mood) W0 
disorder*) or mental* ill* or cyclothym*) ) 
91,034 
 
S5 (MH "Affective Disorders, Psychotic")  346 
 
S4 (MH "Cyclothymic Disorder") 9 
S3 (MH "Dysthymic Disorder") 169 




S1 (MH "Affective Disorders") 3,036 
 
Epistemonikos 
Date for search: 19.09.2017 
(title:(psychoeducat* OR psycho-educat* OR group-intervention* OR family-intervention*) OR 
abstract:(psychoeducat* OR psycho-educat* OR group-intervention* OR family-intervention*)) AND 
(title:(depress* OR dysthym* OR affective-disorder* OR mood-disorder* OR cyclothym*) OR 






6.3 Appendix 3: Excluded studies read in full text   
 
41 excluded studies after full text reading. 
Study Reason for exclusion 
Allart-Van Dam, E., Hosman, C. M. H., Hoogduin, C. A. L. & Schaap, 
C. P.D.R. (2003). The coping with depression course: Short-term 




Alvarado, R., Rojas, G., Minoletti, A., Alvarado, F. & Domínguez, C. 
Ruben Alvardo Depression Program in Primary Health  
Depression Program in Primary Health Care, The Chilean Experience. 




Bersani, F. S., Biondi, M., Coviello, M, Fagiolini, A., Majorana, M., 
Minichino, A., Rusconi, A. C., Vergani, L., Vicianza, R. & Coccanari 
de’ Fornari, M. A. (2017). Psychoeducational intervention focused on 
healthy living improves psychopathological severity and lifestyle quality 
in psychiatric patients: Preliminary findings from a controlled study. 
Journal of Mental Health, 26 (3), 271-275, 
DOI:10.1080/09638237.2017.1294741. 
Mixed diagnosis 
Brown, J. S. L., Elliott, S.A., Boardman, J., Ferns, J. & Morrison, J. 
(2004). Meeting the unmet need for depression services with psycho-
educational self-confidence workshops: prelimenary report. British 
Jounal of Psychiatry, 185, 511-515. 
Comorbidity (anxiety) 
Brown, J. S. L., Elliott, S.A., Boardman, J., Andiappan, M., Landau, S. 
& Howay, E. (2008). Can the effects of a 1-day CBT psychoeducational 
workshop on self-confidence be maintained after 2 years? A naturalistic 
study. Depression and Anxiety, 25, 632-640. 
Comorbidity (anxiety) 
Canasas, R., Catalan, R., Penades, R., Real, J., Valero, S., Munoz, M.A., 
Lalucat-Jo, I.L. & Casas, M. (2014). Evaluation of the Effectiveness of a 
Psychoeducational Intervention in treatment-Naïve Patients with 
Antidepressant Medication in Primary Care: A Randomized Controlled 





Chiesa, A., Mandelli, L., Serretti, A. Alberto Chiesa. (2012). 
Mindfulness-based cognitive therapy versus psycho-education for 
patients with major depression who did not achieve remission following 
antidepressant treatment: a preliminary analysis. J Altern Complement 
Med., 18(8), 756-60. doi: 10.1089/acm.2011.0407 
Wrong comparison 
Conradi, H.J., de Jonge, P. & Ormel, J. (2008). Cognitive-behavioural 
therapy v. usual care in recurrent depression. Br J Psychiatry, 193 (6). 
doi: 10.1192/bjp.bp.107.042937. 
Not group intervention. 
Cramer, H., Salisbury, C., Conrad, J., Eldred, J. & Araya R. (2011). 
Group cognitive behavioural therapy for women with depression:pilot 
and feasibility study for a randomised controlled trial using mixed 
methods.. BMC Psychiatry, 11 (82). 
Pilot study without 
results 
Delgadillo, J., McMillan, D., Lucock, M., Leach, C., Ali, S.&  Gilbody, 
S. (2014). Early changes, attrition, and dose–response in low intensity 
psychological interventions. British Journal of Clinical Psychology,53, 
114-130.  doi.org/10.1111/bjc.12031 
A large proportion of 
the patients have anxiety 
as comorbidity 
Dunn, E., Rogers, E.S., Hutchinson, D.S., Lyass, A., MacDonald, K.L., 
Wallace, L.R. & Furlong-Norman, K. (2008). Results of an Innovative 
University-based Recovery Education Program for Adults with 
Psychiatric Disabilites. Adm Policy Ment Health, 35, 357-369. DOI 
10.1007/s10488-008-0176-9 
Wrong intervention 
Fiorillo, A., Malangone, C., Vecchio, V., Rosa, C., Luciano, M., Giacco, 
D., Sampogna, G., Gaudio, L. & Maj, M. (2011). The effect of family 
psychoeducational interventions on patients with depression. European 
psychiatry [abstracts from the 19th European congress of psychiatry, 
EPA 2011 MAR 12-15; Vienna, Austria]  
Congress abstract  
Franchini, L., Bongiorno, F., Spagnolo, C., Florita, M., Santoro, A., 
Dotoli, D. & Barbini, B. (2006). Smeraldi, E. Psychoeducational group 
intervention in addition to antidepressant therapy as relapse preventive 
strategy in unipolar patients. Clinical Neuropsychiatry, 3 (4), 282-285. 
Patients in remission 
Haringsma, R., Engels, G. I., Cuijpers & P., Spinhoven, P. (2006). 
Effectiveness of the Coping With Depression (CWD) course for older 
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6.5 Appendix 5: Characteristics of the included studies and 
risk of bias  
6.5.1 Aagaard 2017  
Methods Design: Randomized control trial, multicentre. 
Participants Sample size: 80 
Inclusion criteria: ICD-10 recurrent depression (100% severe) 
Exclusion criteria: No specific exclusion criteria were used 
Gender: 71% females, 29 % males 
Age mean: 48 
Setting: Outpatients at 4 Community Mental Health Centres (CMHC) in Denmark 
Interventions Intervention: 
Group Psychoeducation Programme(PEP) based on own 130 pages manual, for 
groups of patients (6-8), one session including family member. 
Dose: 120 minutes weekly, 8 sessions 
+ Treatment as usual (TAU), Antidepressant (52,4%) 
Control group: 2 years outpatient follow by CMHCs, antidepressant (36,8%) 
Outcome measurement points: 6 months, 18 months, 24 months 
Therapists: Highly experienced group therapists or therapists under training 
Outcomes Decline in Beck's depression inventory (BDI) and decline in psychiatric inpatient 
service, Drop-out/non compliance, psychotropic drugs and social measurements 
Notes  
 









"Each CMHC had received two boxes with numbered closed envelopes 







Low risk Closed envelopes. There were some differences in the groups as follows: 
Significant differences at 95% level of marital status (64,3% for cases 
and 36,8% for controls) and absent due to illness for patients attached to 






No blinding of patients nor therapists. 




BDI is self-report. The patients are not blinded (already assessed as high 
risk). 
Incomplete outcome 
data (attrition bias) 
High risk 3 drop outs from intervention group and 11 from control group (28,9%). 
Missing BDI data from 11 patients in control group. However reason and 
numbers are reported; two elderly patients died of ischemic heart disease, 





All expected outcome appear to be reported. 
Other bias Low risk No other bias suspected. 
6.5.2 Casañas 2012  
Methods Design: Randomized controlled trial 
Participants Sample size:231 
Recruitment: By General Practitioners and nurses from 12 primary care centers in 
Barcelona. 
Inclusion: MDD according to ICD-10 Depressive Disorder; BDI >10 and BDI<30 
(mild or moderate depression). Patients older than 20 years. Signed informed 
consent. 
Exclusion: Other psychiatric disorder (including substance abuse), suicidal, using 
2. mental health services, acute & terminal illness, Inability to speak and 
understand local language. Sensory or cognitive disabilities, illiteracy, temporary 
resident on non-provision of consent. Antidepressant not changed during the 
previous months. 




Age mean: 53,8 
Setting: Primary Care (PC), Barcelona, Spain 
Interventions Intervention: 
Group psychoeducation, 12 groups at different PCCs, consisting of 8-12 
participants. The researcher developed a protocol with a program in order to 
homogenize the study intervention. See program in table 1, p. 4 of article. 
Dose: 90 minutes weekly, 12 sessions 
+TAU, Antidepressant (71%) 
Control group: TAU+ Antidepressant (58%) 
Therapist: Two nurses 
Outcome measurement points: 3, 6 and 9 months 














The participants were randomly allocated to one of two conditions by means 




Low risk "An independent person was responsible for managing the randomization 
lists in a sealed envelope to the two nurses at each PCC a few days before 






Patients and therapists not blinded. 










data (attrition bias) 
Low risk The overall drop-outs rate was reported to be 23% after 3 months. The long-
term drop outs rate after 9 months was a lot higher (56%). In total 72 
patients from intervention group and 58 from control group dropped out 
during the whole period. The authors writes that there was no statistically 
difference between the drop outs of the two groups after 3 months follow up. 
Resons for drop outs were: not contactable by telephone and did not attend 
the interview with the nurse (42), not interested in the study (1), change of 
adress (3), referred to a secondary mental health service (2) and other 





Study protocol available. All prespecified outcome reported. 
Other bias Low risk No other bias suspected. 
6.5.3 Chetty 2013  
Methods Design: Randomized control trial 
Participants Sample size: 30 
Recruitment: A poster displayed 6 weeks prior to the study start, informed female 
patients with a diagnosis of depression attending the clinic about the proposed 
study and it purpose. 
Inclusion criteria: Understand English, be indian, reside in the south of Durban, 
age between 25-65 years, diagnosed as depressed either by clinical features or by 
DSM 4 diagnosed by a Medical Officer or a Psychiatric at the clinic. BDI score > 
9 and < 29 (mild to moderate depression). Have been on antidepressant medication 
prescribed at the clinic by the Psychiatrist or the Medical Officer for 3 months or 
more. 
Exclusion criteria: Not specified 
Gender: 100% females 
Age mean: 45,2 
Setting: Urban-community-psychiatric-clinic in South Africa 
Interventions Intervention: 
Nurse-facilitated-cognitive-group (FCG) intervention followed principles of the 
cognitive group therapy program, as indicated in the Verona Gordon's (1988) 
Women's workbook and Facilitator's Manual. Patient groups. 




+Usual treatment: Monthly follow up by nurses to collect medications, 
Antidepressant (66,76% TCA +33,33% TTCA) 
Control group: Usual treatment = no psychotherapeutic-treatment but use of 
antidepressant (86,76% TCA and 13,33% TTCA). Monthly meetings with a 
psychiatric nurse and referred to a doctor in case of complications. 
Therapist: Nurses 
Outcomes measurement points: At 6 and 12 weeks after intervention baseline. 












Low risk "30 consenting participants were selected and randomly allocated to the 
two groups". 30 cards were kept in a hat with coded alphabets (C/G, 
N/FC/G).The hat with the cards was folded and the participant were 









Patients and therapists not blinded. 




BDI is self-reported. The patients are not blinded (already assessed as 
high risk). 
Incomplete outcome 
data (attrition bias) 





All expected outcomes appear to be reported. 
Other bias Low risk No other bias suspected. 
6.5.4 Cohen 2010  




Participants Sample size: 35 
Recruitment: Newspaper ads, radio, TV announcement, flyers, and pamphlets sent 
to local clinics in Long Island,US, all of which described a free therapy program 
for couples struggling with depression. 
Inclusion: The majority had MDD, and some had Dysthymia. BDI-2> 21 
Exclusion: Male caregiver should not be clinical depressed Severely discordant 
couples were referred to other treatment. Infidelity, domestic violence. 
Gender: 100% females 
Age mean: 43,74 
Location: Outpatients, Long Island, US. 
Interventions Intervention: Brief, problem-focused couple therapy for depression-a treatment 
that combined psychoeducational and cognitive-behavioral marital therapy 
approaches to working with couples in which one partner was depressed. Patient 
and caregiver in group. 
Dose: 5 sessions weekly, 120 minutes 
+TAU, Antidepressant (39%), Individual psychotherapy (17%) 
Control group: Waiting list (TAU), Antidepressant (94%), Individual 
psychotherapy (29%) 
Therapist: Advance clinical doctoral student and first author 
Outcomes measurement points: at 5 weeks and 3 months 
Outcomes Depression symptom reduction: BDI-2 and HAM-D, spouse impact (FSDS), 













"Eligible couples were randomized to either the treatment or waiting 








Blinding of participants 
and personnel 
(performance bias) 
High risk Participants are not blinded. The author states that clinicians who 
provided the treatment did not have access to information about the 
couple group assignment. Unclear information. 
Care protocol is standardized and the therapists are evaluated, 
recordings are taken of the sessions. 




"A second diagnostician independently rated 25% of these interviews 
selected randomly at each time point". 
Incomplete outcome 
data (attrition bias) 
High risk Out of 35 in total (18 /17), it was at post assessment a number of 
16/14 who completed but only 15/12 completed the follow up after 
three months. Loss to follow up = 23% ( 17% vs 29,5%). Reasons for 




Blinding of personell. 
Other bias Low risk No other bias suspected. 
6.5.5 Dalgard 2006  
Methods Design: Randomized controlled trial 
Participants Sample size: 155 
Recruitment: Advertisement in Oslo newspaper (Aftenposten), failed to 
recruitment among GPs at primary care. Description about the intervention and 
expected effect. 
Inclusion criteria: Adults (>18 years) with unipolar depression according to DSM 
4. BDI mean= 21.8/22.9 (moderate depression) 
Exclusion criteria: Psychosis, sub clinical depression, other psychiatric diagnosis, 
risk of suicide, preference for other therapy, lack of cognitive skills, other reasons. 
Gender: 76,1 % females, 23,9 % males. 
Age mean: 47,3 




Interventions Intervention: Group PE course, modified version of the coping with depression 
course (CWD) from the ODIN study. Additional booster sessions and more theory. 
Patients group. 
Dose: 8 weeks, 2,5 hours sessions, plus booster sessions at 1,2 and 4 months 
+ TAU for those who wanted, Antidepressant (44,4%),  
Individual psychotherapy at inclusion (24%) 
Therapist: Nurses and students 
Control group: TAU, Antidepressant (42,7%), Individual psychotherapy at 
inclusion (12,7%) 
Outcomes Changes of BDI scores, with a change of more than 6 BDI considered as reliable 
and interesting, and BDI 10 as cut off point for depression 














"Every second person on a list of names (N=155) was assigned to the 
intervention group, the others to the control group". "The sequence of 
names on the list was ordered according to time of recruitment". This is 






Not described. There is a significant difference in age between the 
groups. Logistics regression analysis were adjusted for age, sex, marital 






Patients and therapists not blinded. 




BDI is self-reported. Blinding of Data analyzer performed. 
Incomplete outcome 
data (attrition bias) 
Low risk 
No ITT. Author claims ITT is performed but looking at the table at page 




states on page 5 that N=26 were excluded from the analysis. Lost to 





All expected outcomes appear to be reported. However, the protocol was 
published after the report. 
Other bias Unclear 
risk 
Researcher bias; the activity is developed by the investigator who 
profited from sales of course materials. 
6.5.6 Dowrick 2000  
Methods Design: Randomized controlled trial, multi center. 
Participants Sample size: 425 
Recruitment: Two stage community survey 
Inclusion criteria: 18-65-year-old. Diagnosed with Depressive Disorder, about 
71% w/MDD 
Exclusion criteria: Comorbid psychotic condition, drug or alcohol related disorder 
and major suicide risk. 
Gender: 75,3% females, 24,7% males 
Age mean: Age reported as stratified data 
Setting: Outpatients, Finland, Ireland, Norway, Spain and UK, rural and urban 
Interventions Intervention: Problem solving treatment (128) and Course on prevention of 
depression (108). Patient groups. 
Dose Problem Solving treatment: 6 weeks, individual sessions, less than 4 hours 
Dose Course prevention of depression: 12 sessions of 2 hour, over 8 weeks, groups 
of patients only. 
TAU: Antidepressant not an exclusion criterion, the patients have access to health 
services. 
Therapist: Community health worker. Allied health professional. 
Control group: No treatment/TAU; patients have access to health services 
Outcomes Acceptability of two interventions (withdrawals) 
Caseness (FS-36) 




Subjective function (SF-36) 
Outcomes measurement points: 6 and 12 months 
Notes No other bias suspected 
 
 




Support for jugement 
Random sequence generation 
(selection bias) 
Low risk Allocation schedules were generated by random number tables 





Cases were randomly allocated to one of the three groups.  
Blinding of participants and 
personnel (performance bias) 
High risk 
Patients and therapists not blinded. 
Blinding of outcome 
assessment (detection bias) 
Low risk BDI & SF-36 are self-reported. The patients are not blinded 
(already assessed as high risk). 
Incomplete outcome data 
(attrition bias) 
Low risk High number of loss to follow up but equal in both groups; 30% . 
Those who are lost had severe depression. Inputation of data 




All expected outcomes appear to be reported. 
Other bias Low risk No other bias suspected. 
6.5.7 Günadyɩn 2017 
Methods Design: Semi-experimental trial 
Participants Sample size: 153 
Recruitment: Patients who were in psychiatric policlinic of a state hospital during 
one month and diagnosed for the first time with MMD. 
Inclusion and exclusion criteria: Unipolar depression diagnosed based on DSM-4 
criteria. BDI between 17-30 (moderate to severe depression). 
Treatment plan have included that patient should take antidepressant and for the 




previously hospitalised, not using any oral or depot antipsychotic medications. No 
learning disability, organic brain disease or substance or alcohol abuse. 
Gender: 92,2% females, 7,8% males. 
Age mean: Age reported in intervals, no mean reported. 
Setting: Policlinic, Istanbul, Turkey 
Interventions Intervention: Group PE (Continuity Enhancement Therapy for Antidepressant 
(CETA), focusing on drug compliance & side effects. 
2 Intervention groups: 
1. Group PE (CETA) + usual care including antidepressant 
Dose: 5 weekly sessions, 45-60 minutes 
Groups consisting of patients 
2. Indivual brochure CETA) and antidepressant + TAU 
Therapist: Psyhiatric nurse 
Control group: Antidepressant only/TAU 
Outcomes Depression symptoms (BDI) 








Support for jugement 
Random sequence generation 
(selection bias) 
Unclear risk The authors states: " Ranomization methods were employed to 
achieve homogeneity among the groups" without further 




No description provided. 
Blinding of participants and 
personnel (performance bias) 
High risk 




Blinding of outcome 
assessment (detection bias) 
Low risk BDI is self-reported. The patients are not blinded (already 
assessed as high risk). 
Incomplete outcome data 
(attrition bias) 
Unclear risk 
No description provided. 
Selective reporting (reporting 
bias) 
Low risk 
All pre-specified outcomes are reported. 
Other bias Low risk No other bias suspected. 
6.5.8 Kumar 2015  
Methods Design: Randomized controlled trial 
Participants Sample size: 80 
Inclusion criteria patient: Diagnosed with ICD-10 Depressive Disorder (Severe, 
moderate and mild) 
Exclusion criteria: Any comorbid physical illness, comorbid psychiatric illness, 
substance use disorder, bipolar disorder, partial treated or current treatment for 
depression. Age under 14 and above 60. 
Exclusion criteria care giver: Age < 18, significant medical or mental disorder, 
alchohol or other substance abuse disorder. 
Gender: 61,25% females, 38,75% males. 
Age 15-59 yeas, mean: 36,17 
Setting: Psychiatric clinic, department of Psychiatry of of Vardhman Mahavir 
Medical College & Safdarjung Hospital, India 
Interventions Intervention: Family Psychoeducation, including caregiver 
Dose: 4 sessions over 12 weeks 
TAU including unstructured councelling 
Therapist: Researcher 
Control group: TAU including unctructured councelling 
Outcomes Decline in depression; Hamilton Depression Rating Scale (HDRS), Global 













Support for judgement 
Random sequence 
generation (selection bias) 
Unclear risk "A total of 80 eligible subjects were recruited from the hospitals 
psychiatric department and they were randomised alternately into 2 




No information provided. 




Patients and therapists not blinded. 




"To minimise bias, outcome measures were rated by a psyciatrist 
not involved in the psychoeducation". No blinding of assessor. 
Incomplete outcome data 
(attrition bias) 
Low risk Only 8 patients were lost to follow up: 5% from intervention group 




All expected outcomes appear to be reported. 
Other bias Low risk No other bias suspected. 
6.5.9 Sharif 2012  
Methods Design: Randomsied controlled trial 
Participants Sample size: 60 
Recruitment: Admitted to psychiatric units of hospitals and met criteria. 
Inclusion/exclusion: MDD, age >18 years, not having other mental disoreder, no 
delusion or hallucination and able to participate in a group, the depression was not 
due to psysical disease or bipolar disorder. 
Gender: 55% females, 45% males 




Setting: Inpatients, two hospitals in Shiraz-Iran. 
Interventions Intervention: Group PE 
Dose: 6 weekly sessions, 90 minutes 
Groups consisting of patients only. 
Therapist: Not specified 
Medication 
Control group: TAU+ medication. 
Outcomes Health related quality of life (SF-36) 












Unclear risk " They were randomly assigned into the experimental and control 
groups after considering the preintervention baseline measurement 





No information provided. 




Patients and therapists not blinded. 




No blinding of researcher. The patients are not blinded (already 
assessed as high risk). 
Incomplete outcome data 
(attrition bias) 




Unclear risk All expected outcomes appear to be reported. FS-36 is the only 
outcome measure. As the patients are treated for depression we find 










    
6.6 Appendix 6: Outcomes overview per study 
6.6.1 Aagaard 2017 
 
Use of psychiatric hospital service during 2 years before and 2 years after the date of inclusion: 
  Cases  Controls  
Number of 
admissions: 
Before After Before After 
0 15 (36%) 30 (71%) 13 (34%) 28 (74%) 
1 17 (40%) 10 (24%) 15 (39%) 9 (24%) 
2 8 (19%) 2 (5%) 8 (21%) 1 (3%) 
3 2 (5%) 0 2 (5%) 0 
Total 42 42 38 38 
Duration, days         
Mean (SD) 33,5 (42,7) 5,0 (16,2) 47,0 (63,7) 8,5 (19,9) 
Median (SD) 26 (0-195) 0 (0-82) 15,5 (0-209) 0 (0-97) 
  
Beck’s depression inventory (BDI sum scores) at 6 month intervals during 2 years after the date 
of inclusion of data: 
   Cases   Controls   
  N Mean SD n Mean SD 
6 months 40 17,5 12,6 35 17,5 12,4 
12 months 40 18,8 13,6 31 16,0 11,6 
18 months 39 14,6 12,0 31 15,5 12,2 





6.6.2 Casañas 2012 
 
Remission of depression in the overall, mild and moderate sample: 








    (n=112) (n=119)       
Overall 3 21 (18,75) 41 (34,45) 15,70 (4,5 to 26,9) 0,003 
  6 30 (26,79) 48 (40,34) 13,55 (1,5 to 25,6) 0,014 
  9 30 (26,79) 48 (40,34) 13,55 (1,5 to 25,6) 0,014 
    (n=37) (n=48)       
Mild 3 15 (31,30) 21 (56,80) 25,50 (5,01 to 46) 0,009 
  6 20 (41,70) 22 (59,50) 17,80 (-3,3 to 39) 0,051 
  9 18 (37,50) 24 (64,90) 27,40 (6,7 to 48) 0,006 
    n=82 N=64       
Modera
te 
3 6 (9,40) 20 (24,40) 15,00 (2,7 to 27,2) 0,007 
  6 10 (15,60) 26 (31,70) 16,10 2,2 to 29,9) 0,011 
  9 12 (18,80) 24 (29,30) 10,50 ( - 3,4 to 24,5) 0,068 
  
Overall, mild and moderate sample. Changes in BDI within and between the intervention and 
usual care group with missing data replaced using last value carried forward: 
      Usual Care 
group 
(n=112) 
    Interventi
on group 
(n=119) 






















  3 17,54 
(7,18) 






















0,64 -1,13 (-3,27 
to 0,992) 
0,293 0,15 
  9 16,35 
(7,84) 











      Usual care 
group 
(n=48) 
    Interventio
n group 
(n= 37) 
        
  3 13,23 
(5,57) 








0,71 -2,85 (-5,16 
to -0,542) 
0,016 0,51 
Mild 6 13,15 
(6,02) 












  9 12,27 
(5,78) 











      Usua care 
group (n= 
64) 
    Interventio
n group 
(n= 82) 
        
  3 20,8 
(6,6) 






















  9 19,4 
(7,8) 







0,74 -1,89 (-4,60 
to 0,840) 
0,174 0,24 
SRM= Stanardized response mean 




Overall, mild and moderate sample. Changes in the EQ-5D within and between the intervention 
and usual care group with missing data replaced using last value carried forward: 




    Interventio
n group 
(n=119) 
  Difference (95% CI) 
between groups 
(intervention group-
usual care group) 
    
























0,50 4,19(-0,31 to 8,66) 0,067 0,26 













0,34 0,81(-4,12 to 5,73) 0,748 0,05 












0,43 1,54(-3,43 to 6,51) 0,543 0,09 
      Usual 
care 
(n=48) 




        












0,44 4,99(-2,11 to 12,09) 0,166 0,31 













0,31 3,05(-4,43 to 10,53) 0,420 0,18 












0,48 5,26 (-2,39 to 12,92) 0,175 0,35 




    Interventio
n group 
(n=82) 
        














































0,40 1,30(-5,00 to 7,61) 0,684 0,07 
  
6.6.3 Chetty 2013 
 
The mean Beck Depression Inventory scores for the two groups at the scoring sessions 
  Intervention group (NFCG) Control Group (CG) P value 
Post-test (6 weeks) 17,90 20,70 0,096 
Post-test (12 
weeks) 
14,60 21 <0,001 
p-value <0,001 0,597   
  
6.6.4 Cohen 2010 
 




   3 Months 
follow-up 
   
Outcome-
measure 
M SD t d M SD T D 
BDI-2(W)                 
Treatment 20,34 13,48 0,93 0,34 14,41 10,56 1,60 0,62 
Control 25,28 13,86     26,92 17,16     
HAM-D(W)                 
Treatment 18,38 10,77 1,92 0,70 13,60 11,43 2,81 1,09 
Control 26,29 10,55     26,42 12,25     
FDSD(H)                 




Control 50,91 13,06     48,86 15,26     




40,00 7,13 2,04 0,87 42,40 9,12 2,24 0,86 




40,44 4,57 1,93 1,32 41,80 5,53 2,83 1,28 
Control(Husban
d) 
34,06 5,08     35,66 3,89     
DAS                 
Treatment 
(Wife) 
100,6 20,52 1,02 0,37 102,07 22,77 1,10 0,43 
Control (Wife) 91,87 23,54     92,94 19,77     
Treatment 
(Husband) 
108,7 19,86 1,34 0,42 108,96 16,65 1,64 0,61 
Control 
(Husband) 
100,4 14,00     98,06 18,78     
  
Hieararchical Linear Modeling Results for Effect of Treatment on Change in Outcome 
Variables: 
  B SE t p d 
Outcome Measure           
BDI-2 -0,41 0,16 -2,51 <.01 0,54 
HAM-D -0,47 0,14 -3,44 <.001 0,72 
FDSD -0,42 0,18 -2,31 <.05 0,80 
IRBAS 0,27 0,11 2,54 <.0,1 0,39 





6.6.5 Dalgard 2006 
 
Beck Depression Inventory for intervention group and control group at different measurement 
points: 
    2 months  6 months  
    Mean SD Mean SD 
Males Intervention group 14,0 7,0 14,4 8,8 
  Control group     17,5 7,7 
  Significance     Not significant   
Females Intervention group 15,6 7,8 14,0 9,5 
  Control group     18,7 10,3 
  Significance     P<0,05   
Total Intervention group 15,2 7,6 14,1 9,3 
  Control group     18,3 9,6 
  Significance     P<0,05   
  
6.6.6  Dowrick 2000 
 
Acceptability of problem solving treatment and course on prevention of depression.  
Values are numbers of participants unless stated otherwise. 
PS= Problem Solving 
DP= Depression Prevention 






Did not attend No (%) who 
completed 
treatment 
1 PS 23 0 5 1 17 (74) 




3 DP 7 0 2 2 3(43) 
4 DP 8 0 1 4 3(38) 
5 DP 42 15 5 0 22(52) 
6 DP 36 12 5 2 17(47) 
7 PS 19 7 0 0 12(63) 
8 PS 32 5 7 4 16(50) 
8 DP 15 5 1 6 3(20) 
9 PS 26 5 6 0 15(58) 
  N0 (%) 
problem 
solving 
128 20(16) 22 (17) 6 (5) 80 (63) 
  N0 (%) 
depression 
prevention 
108 32 (29) 14 (13) 14 (13) 48 (44) 
  





  Proportions not 
depressed (%) 
  
  6 
months 
  12 months   






Control group Treatment 
group 
Difference 
Centre             
1-PS 8/9(42) 11/19(58) 16 9/17(53) 11/16(69) 16 
2-PS 12/20(60
) 
20/24(83) 23 13/20(65) 13/22(59) -6 
3-DP 3/6(50) 5/5(100) 50 5/7(71) 4/4(100) 29 




5-DP 9/17(53) 18/31(58) 5 8/16(50) 18/35(51) -1 
6-DP 6/18(33) 12/32(38) 4 10/18(56) 14/31(45) -10 
7-PS 2/6(33) 8/15(53) 20 5/7(71) 11/17(68) -7 
8-PS 10/31(32
) 
12/22(55) 22 16/25(64) 12/19(63) -1 
8-DP 10/31(32
) 
7/9(78) 46 16/25(64) 5/8(63) -2 
9-PS 8/18(44) 7/18(39) -6 8/13(62) 8/15(53) --8 
Total PS 40/94(43
) 
58/98(59) 17* 50/82(61) 55/89(62) 1** 
Total DP 32/78(41
) 
44/80(55) 14*** 43/72(60) 44/83(53) -7**** 
*Odds  ratio 1,39, number needed to treat 6. 
**Odds ratio 1,01. 
***Oddsratio 1,34, number needed to treat 7. 
**** Odds ratio 0,89. 
 
Logistic regression estimates of treatment effects on 
diagnosis of depressive disorders. Values are odds ratios 
(95% confidence intervals), with controls as reference: 
  
  6 months 12 months 
Unweighted(complete case analysis)     
Problem solving 0,51(0,27 to 0,97) 0,92(0,48 to 1,77) 
Depression prevention 0,50(0,21 to 1,15) 1,02(0,46 to 2,23) 
Weighted (to allowe for missing outcomes)     
Problem solving 0,58(0,34 to 1,09) 0,87(0,45 to 1,70) 
Depression prevention 0,47(0,20 to 1,12) 1,07(0,46 to 2,48) 
  
Outcomes for Beck depression Inventory and SF-36 at 6 
months and 12 months. Values are overall means (SD) 
  




Controls 14,97(10,23) 12,60(9,50) 
Problem Solving 12,48(9,95) 11,15(9,20) 
Depression prevention 14,26(9,71) 14,60(8,75) 
SF-36     
Mental role:     
Controls 51,71(42,70) 63,62(41,90) 
Problem solving 63,91(42,13) 70,53(37,38) 
Depression prevention 64,90(40,70) 61,43(40,48) 
Social function:     
Controls 64,90(32,46) 70,39(30,09) 
Problem solving 73,39(28,81) 75,42(29,28) 
Depression prevention 68,31(29,07) 66,89(27,33) 
Mental health:     
Controls 53,71(23,58) 60,51(22,39) 
Problem solving 60,08(21,09) 62,79(22,00) 
Depression prevention 59,54(21,41) 57,11(20,33) 
  
Outcomes for 
treatment effects at 6 
and 12 months 
     
   6 months  12 months  
Treatment v control Outcome Mean (95% CI) P value Mean (95% 
CI) 
P value 
Problem solving BDI -2,63(-495 to -
0,32) 
0,026 -1,00(-3,31 to 
1,31) 
0,398 
















0,012 6,96(-0,74 to 
14,59) 
0,077 





0,005 4,14(-0,99 to 
9,28) 
0,114 
Depression prevention BDI -1,50(-4,16 to 
1,17) 
0,272 1,11 (-1,30 to 
3,52) 
0,901 





0,042 -4,02(-14,53 to 
6,49) 
0,454 





0,048 2,36(-6,10 to 
10,83) 
0,584 









6.6.7 Günadyɩn 2017 
 
Comparison of pre/post-education depression scores of the groups 
  After 1 month of 
education the average 
depression scores 
After 3 month of 
education the average 
depression scores 
After 6 month of education the 
average depression scores 
Groups (M+/- SD) (M+/- SD) (M+/- SD) 
PE group (n=49) 18,00 +/-11,50 17,53 +/- 12,01 11,18 +/- 10,36 
Drug group (n=53) 19,73 +/- 10,46 18,59 +/- 13,72 16,6 +/- 12,95 
Brochure group 
(n=51) 
18,94 +/- 9,21 16,19 +/- 9,78 12,25 +/- 10,01 
  X2 =76.770 X2 = 950.838 X2 = 26.770 





6.6.8  Kumar 2015 
 
Outcome measures: 
  At baseline At 4 weeks At 8 weeks At 12 weeks 
HDRS PE 24,23 +/- 3,00 15,62 +/- 5,25 12,72 +/- 5,10 8,43 +/- 5,90 
HDRS 
Controls 
22,48 +/- 4,31 17,61 +/- 4,92 16,21 +/- 4,82 14,71 +/- 3,40 
          
GAF PE 62 +/- 4,80 72 +/- 6,93 75 +/- 9,20 84 +/- 8,63 
GAF 
Controls 
57 +/- 11,38 62 +/- 9,97 67,56 +/- 8,34 76,1 +/- 6,01 
          
PGWBI PE 27,92 +/- 5,31 52,08 +/- 10,40 72 +/-10,80 87,92 +/- 7,30 
PGWBI 
Controls 
27,42 +/- 6,41 47,52 +/- 9,21 55 +/- 9,15 70,17 +/- 9,28 
          
 
Impact of psychoeducation: 
  At 4 weeks At 8 weeks At 12 weeks 
HDRS PE -8,61 (6,24-10,99) -11,51 (9,76-14,10) -15,80 (11,55-19,61) 
HDRS Controls -4,87 (3,24-7,99) -6,27 (4,22-9,10) -7,77 (4,06-11,29) 
p-Value 0,003 <0,001 <0,001 
GAF PE 10 (6,98-13,02) 13 (10,16-15,43) 22 (13,89-29,11) 
GAF Controls 5 (4,98-8,02) 10,56 (8,86-13,24) 19,1 (12,89-23,45) 
P Value 0,04 0,20 0,03 
PGWBI PE 24,16 (18,64-29,67) 44,08 (42,34-46,63) 60 (55,47-64,68) 




P Value 0,09 0,001 0,001 
  
6.6.9 Sharif 2012 
 
Means score of life quality domains in groups (SF-36) 
  Case group   Control Group   









Physical function 16,7 (3,6) 24,3 (2,6) 0,001 16,9 (4,1) 20,5 (3,09) 0,001 
Role performance 
limitation due to 
physical problems 
-1,16 (1,3) -3,5 (0,8) 0,001 -1,8(1,3) -2,2(0,8) 0,117 
Role performance 
limitation due to 
psychological 
problems 
-0,16 (0,46) -2,4(0,56) 0,001 -0,06(0,25) -0,86(0,68) 0,001 
Social 
performance 
3,2(1,1) 7,9(1,4) 0,001 3,8(1,3) 5,5(1,1) 0,001 
Physical pain -5,3(2,4) -9,2(1,9) 0,001 -6,5(2,04) -7,5(1,5) 0,008 
Psychological 
health 
9,0(2,6) 21,4(3,6) 0,001 9,9(2,3) 15,6(3,1) 0,001 
Vitality 8,8(3,1) 16,8(2,3) 0,001 9,0(2,3) 13,0(2,9) 0,001 
General health 
perception 
13,4(4,2) 23,4(3,9) 0,001 13,7(3,9) 18,2(4,3) 0,001 
 
Means score of life quality domains between groups (before and after) 
 Case M (SD) Control M (SD) P(value) 





limitation due to 
physical problems 
-2,3 (1.1) -0,4(1.4) 0,001 
Role performance  -2,2 (0,5) -0,8 (0,6) 0,001 
Limitation due to 
psychological problems 
   
Social Performance 4,7 (1,5) 1,7 (1,4) 0,001 
Physical pain -3,9 (2,1) -1,0 (2,0) 0,001 
Psychological health 12,4 (4,4) 5,7 (3,6) 0,001 
Hapiness 8,0 (3,5) 4,0 (3,6) 0,001 
General health 
perception 






6.7 Appendix 7: Depression outcomes sorted by time of 
assessment 
 
Depression outcomes assessed at 4 weeks 
Study Comparison Tool I (n) Ctrl 
(n) 
Baseline 
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Efficacy of group 
PE (CETA) + usual 
care  vs. 
antidepressant only 









Depression outcomes assessed at 5 weeks 


















Cohen 2010 Effectiveness of 
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Depression outcomes assessed at 6 weeks 
Study Comparison Tool I (n) Ctrl 
(n) 
Baseline 
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Depression outcomes assessed at 8 weeks 
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Depression outcomes assessed at 3 months 
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14,71     
(3,40) 
 
Depression outcomes assessed at 6 months 
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CWD course + 
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Efficacy of group 
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Antidepressant 
only 












  Depression outcomes assessed at 9 months 
Study Comparison To
ol 





































Depression outcomes assessed at 12 months 
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versus TAU 

























Depression outcomes assessed at 18 months 























GPE  to TAU 
versus TAU 












Depression outcomes assessed at 24 months 
Study Comparison Too
l 























GPE  to TAU 
versus TAU 














6.8 Appendix 8: GRADE evidence profiles 
  
 
The effect of GPE and TAU versus TAU for MDD on depression 
 
Bibliography: Aagaard et al., 2017, Casañas et al., 2012, Cohen, O’ Leary & Foran, 2010, Dalgard, 2006, 
Dowrick et al., 2000, Günadyɩn & Barlas, 2017, Kumar & Gupta 2015.  


















































Effect of GPE and TAU compared to TAU for MDD at 4-6 weeks follow-up 
Bibliography: Cohen, O’ Leary & Foran, 2010, Günadyɩn & Barlas, 2017, Kumar & Gupta 2015. 
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not serious  not 
serious  
serious a none  ⨁⨁⨁◯ 
MODERAT
E  







Effect of GPE and TAU compared to TAU for MDD at 3 months follow-up 
Bibliography: Casañas et al., 2012, Cohen, O’ Leary & Foran, 2010, Günadyɩn & Barlas, 2017, Kumar & 
Gupta 2015.  
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none  ⨁⨁⨁◯ 
MODERAT
E  










Effect of GPE and TAU compared to TAU for MDD at 6 months follow-up 
Bibliography: Aagaard et al., 2017, Casañas et al., 2012, Dalgard, 2006, Dowrick et al., 2000, Günadyɩn & 




The effect of GPE and TAU versus TAU for MDD on depression 
 
Bibliography: Aagaard et al., 2017, Casañas et al., 2012, Cohen, O’ Leary & Foran, 2010, Dalgard, 2006, 
Dowrick et al., 2000, Günadyɩn & Barlas, 2017, Kumar & Gupta 2015.  










none  ⨁⨁⨁⨁ 
HIGH  







Effect of GPE and TAU compared to TAU for MDD at 12 months follow-up 
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not serious  not 
serious  
serious a none  ⨁⨁⨁◯ 
MODERAT
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The effect of FGPE and TAU vs TAU for MDD on psychosocial functioning 
 
Bibliography: Cohen, O’ Leary & Foran, 2010, Kumar & Gupta, 2015 




















































Psychosocial functioning at 4-5 weeks follow-up  
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none  ⨁⨁◯◯ 
LOW  







Psychosocial functioning at 3 months follow-up 
99 








none  ⨁⨁◯◯ 
LOW  













The effect of GPE and TAU vs TAU for MDD on quality of life 
 
Bibliography: Casañas et al., 2012, Dowrick et al., 2000.  
































































Explanations: a. the result is reported differently for the two studies but none of the results show significant difference between the 
intervention group and the control group. 
 
The effect of GPE and TAU vs TAU for MDD on relapse 
 
Bibliography: Aagaard et al., 2017  
Certainty assessment  
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Explanations: a: less than 400 participants   
 
 
 
